Summary of PICO criteria to define the question(s) to be ...



Application 1519:Tisagenlecleucel (CTL019) for treatment of refractory/relapsed CD19-positive leukaemia and lymphomaPICO Confirmation(To guide a new application to MSAC)(Version 2.0)Summary of PICO criteria to define the question(s) to be addressed in an Assessment Report to the Medical Services Advisory Committee (MSAC)Table SEQ Table \* ARABIC 1 PICO criteria for children and young adult patients with acute lymphoblastic leukaemia (population 1)ComponentDescriptionPopulationChildren and young adult patients (3-25 years old) with confirmed relapsed/refractory B-cell acute lymphoblastic leukaemia (ALL). This means patients (listed as sub-populations below) who: Have experienced a second or greater bone marrow relapse; ORHave experienced any bone marrow relapse following allogenic stem cell transplant; ORAre primary refractory (i.e. not achieving a complete response after 2 cycles of a standard chemotherapy regimen); ORAre chemo refractory (i.e. not achieving a complete response after 1 cycle of standard chemotherapy for relapsed leukaemia); ORAre Philadelphia chromosome positive AND intolerant to (or have failed two lines of) tyrosine kinase inhibitor therapy, OR for whom such therapy is contraindicated; ORAre ineligible for allogenic stem cell transplant because of comorbid disease, contraindications to the conditioning regimen, prior SCT, OR lack of a suitable donor.InterventionTisagenlecleucel (also known as CTL019, and brand name Kymriah?)ComparatorAgainst the relevant sub-population (see ‘Population’ above)Best supportive care (or a clinical trial)Salvage chemotherapy with intention to proceed to allogenic SCT, clofarabine with intention to proceed to allogenic SCT, or in some cases: best supportive care or a clinical trial (when refractory after TKI+ chemotherapy and allogenic SCT)Salvage chemotherapy with intention to proceed to allogenic SCT, or clofarabine with intention to proceed to allogenic SCTBest supportive care (or a clinical trial)Best supportive care (or a clinical trial)Best supportive care (or a clinical trial)OutcomesClinical effectiveness:Overall response rate (ORR) and/or complete response rate Relapse-free survival and/or event-free survivalOverall survival (OS)Quality of life (QoL)Health-related quality of life (HRQoL)Rate of complete/partial remissionDuration of responseTime to return to daily activitiesClinical efficacy:Tisagenlecleucel failure ratePercentage of patients successfully receiving tisagenlecleucel after starting the processTime from leukapheresis to receiving tisagenlecleucelSafety:Rate of adverse events (AEs) and serious adverse events (SAEs)events of special interest (e.g. cytokine release syndrome, tumour lysis syndrome, febrile neutropenia)AEs due to medications, neurotoxicity, infections, secondary cancersCost-effectiveness:Cost (including cost of additional pre-infusion and post-infusion interventions)Cost per life year gained (LYG)Cost per quality adjusted life year (QALY) or disability adjusted life year (DALY)Incremental cost-effectiveness ratioFinancial implications:Number of patients suitable for treatmentNumber of patients who receive treatment Table SEQ Table \* ARABIC 2 PICO criteria for adult patients with diffuse large B-cell lymphoma (population 2)ComponentDescriptionPopulationAdult patients (≥ 18 years old) with confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This means patients who have relapsed or refractory disease after at least two lines of chemotherapy, andhave relapsed after autologous stem cell transplant, ORare ineligible for subsequent stem cell transplantInterventionTisagenlecleucel (also known as CTL019, and brand name Kymriah?)ComparatorSalvage chemotherapy (and in some cases a clinical trial) OutcomesClinical effectiveness:Overall response rate (ORR) and/or complete response rate Relapse-free survival and/or event-free survivalOverall survival (OS)Quality of life (QoL)Health-related quality of life (HRQoL)Rate of complete/partial remissionDuration of responseTime to return to daily activitiesClinical efficacy:Tisagenlecleucel failure ratePercentage of patients successfully receiving tisagenlecleucel after starting the processTime from leukapheresis to receiving tisagenlecleucelSafety:Rate of adverse events (AEs) and serious adverse events (SAEs)Events of special interest (e.g. cytokine release syndrome, tumour lysis syndrome, febrile neutropenia)AEs due to medications, neurotoxicity, infections, secondary cancersCost-effectiveness:Cost (including cost of additional pre-infusion and post-infusion interventions)Cost per life year gained (LYG)Cost per quality adjusted life year (QALY) or disability adjusted life year (DALY)Incremental cost-effectiveness ratioFinancial implications:Number of patients suitable for treatmentNumber of patients who receive treatment 2. PICO or PPICO rationale for therapeutic and investigative medical services only2.1 Research questionsAcute lymphoblastic leukaemia (ALL):What is the safety, effectiveness and cost-effectiveness of tisagenlecleucel in children and young adult patients (3-25 years old) with confirmed relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) and a second or greater bone marrow relapse, compared with best supportive care (or a clinical trial)?What is the safety, effectiveness and cost-effectiveness of tisagenlecleucel in children and young adult patients (3-25 years old) with confirmed relapsed or refractory B-cell ALL and a bone marrow relapse following allogenic stem cell transplant (SCT), compared with: salvage chemotherapy with the intention to proceed to allogenic SCT, orclofarabine with intention to proceed to allogenic SCT, orbest supportive care (in some cases), ora clinical trial (when refractory after TKI+ chemotherapy and allogenic SCT)1?What is the safety, effectiveness and cost-effectiveness of tisagenlecleucel in children and young adult patients (3-25 years old) with confirmed B-cell ALL who are primary refractory, as defined by not achieving a complete response after two cycles of a standard chemotherapy regimen, compared with:salvage chemotherapy with intention to proceed to allogenic SCT, or clofarabine with intention to proceed to allogenic SCT?What is the safety, effectiveness and cost-effectiveness of tisagenlecleucel in children and young adult patients (3-25 years old) with confirmed relapsed or refractory B-cell ALL who are chemo refractory, as defined by not achieving a complete response after one cycle of standard chemotherapy for relapsed leukaemia, compared with best supportive care (or a clinical trial)?What is the safety, effectiveness and cost-effectiveness of tisagenlecleucel in children and young adult patients (3-25 years old) with confirmed relapsed or refractory B-cell ALL and who are Philadelphia chromosome positive and intolerant to or have failed two lines of tyrosine kinase inhibitor therapy (or for whom such therapy is contraindicated), compared with best supportive care (or a clinical trial2)?What is the safety, effectiveness and cost-effectiveness of tisagenlecleucel in children and young adult patients (3-25 years old) with confirmed relapsed or refractory B-cell ALL, who are ineligible for allogenic SCT because of comorbid disease, contraindications to the conditioning regimen, prior SCT, or lack of a suitable donor, compared with best supportive care (or a clinical trial2)?Diffuse large B-cell lymphoma (DLBCL): What is the safety, effectiveness and cost-effectiveness of tisagenlecleucel in adult patients (≥ 18 years old) with confirmed diffuse large B-cell lymphoma (DLBCL), who have relapsed or refractory disease after at least two lines of chemotherapy, and have relapsed after autologous SCT, compared with salvage chemotherapy (or a clinical trial2)?What is the safety, effectiveness and cost-effectiveness of tisagenlecleucel in adult patients (≥ 18 years old) with confirmed diffuse large B-cell lymphoma (DLBCL), who have relapsed or refractory disease after at least two lines of chemotherapy, and are ineligible for subsequent stem cell transplant, compared with salvage chemotherapy (or a clinical trial2)?2.2 PopulationPopulation 1: Relapsed or refractory acute B-cell lymphoblastic leukaemia (ALL)ALL occurs when lymphoid progenitor cells in the bone marrow proliferate uncontrollably. This leads to an excess of malignant lymphoblasts, which can then be found in the peripheral blood in large numbers. In 2014, 371 people were diagnosed with ALL (156 females and 214 males). The risk of a diagnosis is 1 in 812 before age 75 and 1 in 756 before age 85. ADDIN EN.CITE <EndNote><Cite><Author>Australian Institute of Health and Welfare (AIHW)</Author><Year>2017</Year><RecNum>11</RecNum><DisplayText>(Australian Institute of Health and Welfare (AIHW) 2017)</DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1517786021">11</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Australian Institute of Health and Welfare (AIHW),.</author></authors></contributors><titles><title>Australian Cancer Incidence and Mortality (ACIM) books: Acute lymphoblastic leukaemia (ALL),</title></titles><dates><year>2017</year></dates><pub-location>Canberra</pub-location><publisher>Australian Institute of Health and Welfare (AIHW)</publisher><urls><related-urls><url>;(Australian Institute of Health and Welfare (AIHW) 2017) Figure SEQ Figure \* ARABIC 1 Incidence rates of ALL by sex and age group at diagnosis (rate per 100,000 population) ADDIN EN.CITE <EndNote><Cite><Author>Australian Institute of Health and Welfare (AIHW)</Author><Year>2017</Year><RecNum>11</RecNum><DisplayText>(Australian Institute of Health and Welfare (AIHW) 2017)</DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1517786021">11</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Australian Institute of Health and Welfare (AIHW),.</author></authors></contributors><titles><title>Australian Cancer Incidence and Mortality (ACIM) books: Acute lymphoblastic leukaemia (ALL),</title></titles><dates><year>2017</year></dates><pub-location>Canberra</pub-location><publisher>Australian Institute of Health and Welfare (AIHW)</publisher><urls><related-urls><url>;(Australian Institute of Health and Welfare (AIHW) 2017)ALL is the most common type of cancer in children, with around 60% of cases diagnosed in children. Most patients are between 2 and 5 years old when they are diagnosed. In 2015, 119 ALL patients in Australia died (51 males and 68 females). This means the risk of death from ALL is 1 in 3193 before age 75 and 1 in 1948 before age 85 ADDIN EN.CITE <EndNote><Cite><Author>Australian Institute of Health and Welfare (AIHW)</Author><Year>2017</Year><RecNum>11</RecNum><DisplayText>(Australian Institute of Health and Welfare (AIHW) 2017)</DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1517786021">11</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Australian Institute of Health and Welfare (AIHW),.</author></authors></contributors><titles><title>Australian Cancer Incidence and Mortality (ACIM) books: Acute lymphoblastic leukaemia (ALL),</title></titles><dates><year>2017</year></dates><pub-location>Canberra</pub-location><publisher>Australian Institute of Health and Welfare (AIHW)</publisher><urls><related-urls><url>;(Australian Institute of Health and Welfare (AIHW) 2017). Common treatments include chemotherapy, peripheral blood stem cell and bone marrow transplantation, steroid therapy and radiotherapy to the head. A large childhood ALL cohort was followed in the US. The 5-year survival rates for ALL patients were 53% for children < 1 year old 94%, 82%, 85% and 75% for patients aged 1-9.9 years, > 10 years, 10-14.9 years, and ≥ 15 years (from 2000-2005) PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IdW5nZXI8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxS

ZWNOdW0+MTwvUmVjTnVtPjxJRFRleHQ+MTY2My05PC9JRFRleHQ+PERpc3BsYXlUZXh0PihIdW5n

ZXIgZXQgYWwuIDIwMTIpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjE8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJmZmVzemV3MnA1ZjBmOGUw

ZGY1cHQ1ZHdwZjlmOTJzMHZhZHciIHRpbWVzdGFtcD0iMTUxNTExMDE3NyI+MTwva2V5PjwvZm9y

ZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48

Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+SHVuZ2VyLCBTLiBQLjwvYXV0aG9yPjxhdXRo

b3I+THUsIFguPC9hdXRob3I+PGF1dGhvcj5EZXZpZGFzLCBNLjwvYXV0aG9yPjxhdXRob3I+Q2Ft

aXR0YSwgQi4gTS48L2F1dGhvcj48YXV0aG9yPkdheW5vbiwgUC4gUy48L2F1dGhvcj48YXV0aG9y

PldpbmljaywgTi4gSi48L2F1dGhvcj48YXV0aG9yPlJlYW1hbiwgRy4gSC48L2F1dGhvcj48YXV0

aG9yPkNhcnJvbGwsIFcuIEwuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRo

LWFkZHJlc3M+VW5pdmVyc2l0eSBvZiBDb2xvcmFkbyBTY2hvb2wgb2YgTWVkaWNpbmUsIENoaWxk

cmVuJmFwb3M7cyBIb3NwaXRhbCBDb2xvcmFkbywgQXVyb3JhLCBDTyA4MDA0NSwgVVNBLiBzdGVw

aGVuLmh1bmdlckBjaGlsZHJlbnNjb2xvcmFkby5vcmc8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0

aXRsZT5JbXByb3ZlZCBzdXJ2aXZhbCBmb3IgY2hpbGRyZW4gYW5kIGFkb2xlc2NlbnRzIHdpdGgg

YWN1dGUgbHltcGhvYmxhc3RpYyBsZXVrZW1pYSBiZXR3ZWVuIDE5OTAgYW5kIDIwMDU6IGEgcmVw

b3J0IGZyb20gdGhlIGNoaWxkcmVuJmFwb3M7cyBvbmNvbG9neSBncm91cDwvdGl0bGU+PHNlY29u

ZGFyeS10aXRsZT5KIENsaW4gT25jb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9k

aWNhbD48ZnVsbC10aXRsZT5KIENsaW4gT25jb2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxw

YWdlcz4xNjYzLTk8L3BhZ2VzPjx2b2x1bWU+MzA8L3ZvbHVtZT48bnVtYmVyPjE0PC9udW1iZXI+

PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdlIEZhY3Rv

cnM8L2tleXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQgQ2hlbW90aGVyYXB5

IFByb3RvY29scy9hZG1pbmlzdHJhdGlvbiAmYW1wOyBkb3NhZ2U8L2tleXdvcmQ+PGtleXdvcmQ+

KkNhdXNlIG9mIERlYXRoPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3Jk

PkNoaWxkLCBQcmVzY2hvb2w8L2tleXdvcmQ+PGtleXdvcmQ+KkNsaW5pY2FsIFRyaWFscyBhcyBU

b3BpYzwva2V5d29yZD48a2V5d29yZD5Db2hvcnQgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5E

aXNlYXNlIFByb2dyZXNzaW9uPC9rZXl3b3JkPjxrZXl3b3JkPkRpc2Vhc2UtRnJlZSBTdXJ2aXZh

bDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3

b3JkPjxrZXl3b3JkPkthcGxhbi1NZWllciBFc3RpbWF0ZTwva2V5d29yZD48a2V5d29yZD5NYWxl

PC9rZXl3b3JkPjxrZXl3b3JkPk11bHRpdmFyaWF0ZSBBbmFseXNpczwva2V5d29yZD48a2V5d29y

ZD5OYXRpb25hbCBDYW5jZXIgSW5zdGl0dXRlIChVLlMuKTwva2V5d29yZD48a2V5d29yZD5QcmVj

dXJzb3IgQ2VsbCBMeW1waG9ibGFzdGljIExldWtlbWlhLUx5bXBob21hLypkaWFnbm9zaXMvZHJ1

ZyB0aGVyYXB5Lyptb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25vc2lzPC9rZXl3b3Jk

PjxrZXl3b3JkPlByb3BvcnRpb25hbCBIYXphcmRzIE1vZGVsczwva2V5d29yZD48a2V5d29yZD5S

ZXRyb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBBc3Nlc3NtZW50PC9r

ZXl3b3JkPjxrZXl3b3JkPlNldmVyaXR5IG9mIElsbG5lc3MgSW5kZXg8L2tleXdvcmQ+PGtleXdv

cmQ+U2V4IEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgQW5hbHlzaXM8L2tleXdv

cmQ+PGtleXdvcmQ+VGltZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlRyZWF0bWVudCBPdXRj

b21lPC9rZXl3b3JkPjxrZXl3b3JkPlVuaXRlZCBTdGF0ZXM8L2tleXdvcmQ+PC9rZXl3b3Jkcz48

ZGF0ZXM+PHllYXI+MjAxMjwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1heSAxMDwvZGF0ZT48L3B1

Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE1MjctNzc1NSAoRWxlY3Ryb25pYykmI3hEOzA3MzItMTgz

WCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjI0MTIxNTE8L2FjY2Vzc2lvbi1udW0+

PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt

ZWQvMjI0MTIxNTE8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+MzM4MzExMzwv

Y3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTIwMC9KQ08uMjAxMS4zNy44MDE4

PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IdW5nZXI8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxS

ZWNOdW0+MTwvUmVjTnVtPjxJRFRleHQ+MTY2My05PC9JRFRleHQ+PERpc3BsYXlUZXh0PihIdW5n

ZXIgZXQgYWwuIDIwMTIpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjE8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJmZmVzemV3MnA1ZjBmOGUw

ZGY1cHQ1ZHdwZjlmOTJzMHZhZHciIHRpbWVzdGFtcD0iMTUxNTExMDE3NyI+MTwva2V5PjwvZm9y

ZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48

Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+SHVuZ2VyLCBTLiBQLjwvYXV0aG9yPjxhdXRo

b3I+THUsIFguPC9hdXRob3I+PGF1dGhvcj5EZXZpZGFzLCBNLjwvYXV0aG9yPjxhdXRob3I+Q2Ft

aXR0YSwgQi4gTS48L2F1dGhvcj48YXV0aG9yPkdheW5vbiwgUC4gUy48L2F1dGhvcj48YXV0aG9y

PldpbmljaywgTi4gSi48L2F1dGhvcj48YXV0aG9yPlJlYW1hbiwgRy4gSC48L2F1dGhvcj48YXV0

aG9yPkNhcnJvbGwsIFcuIEwuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRo

LWFkZHJlc3M+VW5pdmVyc2l0eSBvZiBDb2xvcmFkbyBTY2hvb2wgb2YgTWVkaWNpbmUsIENoaWxk

cmVuJmFwb3M7cyBIb3NwaXRhbCBDb2xvcmFkbywgQXVyb3JhLCBDTyA4MDA0NSwgVVNBLiBzdGVw

aGVuLmh1bmdlckBjaGlsZHJlbnNjb2xvcmFkby5vcmc8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0

aXRsZT5JbXByb3ZlZCBzdXJ2aXZhbCBmb3IgY2hpbGRyZW4gYW5kIGFkb2xlc2NlbnRzIHdpdGgg

YWN1dGUgbHltcGhvYmxhc3RpYyBsZXVrZW1pYSBiZXR3ZWVuIDE5OTAgYW5kIDIwMDU6IGEgcmVw

b3J0IGZyb20gdGhlIGNoaWxkcmVuJmFwb3M7cyBvbmNvbG9neSBncm91cDwvdGl0bGU+PHNlY29u

ZGFyeS10aXRsZT5KIENsaW4gT25jb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9k

aWNhbD48ZnVsbC10aXRsZT5KIENsaW4gT25jb2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxw

YWdlcz4xNjYzLTk8L3BhZ2VzPjx2b2x1bWU+MzA8L3ZvbHVtZT48bnVtYmVyPjE0PC9udW1iZXI+

PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdlIEZhY3Rv

cnM8L2tleXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQgQ2hlbW90aGVyYXB5

IFByb3RvY29scy9hZG1pbmlzdHJhdGlvbiAmYW1wOyBkb3NhZ2U8L2tleXdvcmQ+PGtleXdvcmQ+

KkNhdXNlIG9mIERlYXRoPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3Jk

PkNoaWxkLCBQcmVzY2hvb2w8L2tleXdvcmQ+PGtleXdvcmQ+KkNsaW5pY2FsIFRyaWFscyBhcyBU

b3BpYzwva2V5d29yZD48a2V5d29yZD5Db2hvcnQgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5E

aXNlYXNlIFByb2dyZXNzaW9uPC9rZXl3b3JkPjxrZXl3b3JkPkRpc2Vhc2UtRnJlZSBTdXJ2aXZh

bDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3

b3JkPjxrZXl3b3JkPkthcGxhbi1NZWllciBFc3RpbWF0ZTwva2V5d29yZD48a2V5d29yZD5NYWxl

PC9rZXl3b3JkPjxrZXl3b3JkPk11bHRpdmFyaWF0ZSBBbmFseXNpczwva2V5d29yZD48a2V5d29y

ZD5OYXRpb25hbCBDYW5jZXIgSW5zdGl0dXRlIChVLlMuKTwva2V5d29yZD48a2V5d29yZD5QcmVj

dXJzb3IgQ2VsbCBMeW1waG9ibGFzdGljIExldWtlbWlhLUx5bXBob21hLypkaWFnbm9zaXMvZHJ1

ZyB0aGVyYXB5Lyptb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25vc2lzPC9rZXl3b3Jk

PjxrZXl3b3JkPlByb3BvcnRpb25hbCBIYXphcmRzIE1vZGVsczwva2V5d29yZD48a2V5d29yZD5S

ZXRyb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBBc3Nlc3NtZW50PC9r

ZXl3b3JkPjxrZXl3b3JkPlNldmVyaXR5IG9mIElsbG5lc3MgSW5kZXg8L2tleXdvcmQ+PGtleXdv

cmQ+U2V4IEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgQW5hbHlzaXM8L2tleXdv

cmQ+PGtleXdvcmQ+VGltZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlRyZWF0bWVudCBPdXRj

b21lPC9rZXl3b3JkPjxrZXl3b3JkPlVuaXRlZCBTdGF0ZXM8L2tleXdvcmQ+PC9rZXl3b3Jkcz48

ZGF0ZXM+PHllYXI+MjAxMjwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1heSAxMDwvZGF0ZT48L3B1

Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE1MjctNzc1NSAoRWxlY3Ryb25pYykmI3hEOzA3MzItMTgz

WCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjI0MTIxNTE8L2FjY2Vzc2lvbi1udW0+

PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt

ZWQvMjI0MTIxNTE8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+MzM4MzExMzwv

Y3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTIwMC9KQ08uMjAxMS4zNy44MDE4

PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA (Hunger et al. 2012). Five-year survival rates increased from 83.7% to 91.4% between 1990-1994 and 2000-2005. The applicant indicated that approximately 20% of patients will experience at least one relapse, and that each relapse makes maintaining remission more challenging. They stated that patients with a second relapse have few effective treatment options and typically a poor prognosis, with a long term survival of 10%. The applicant proposes that the medical service should be intended for children and young adult patients (3-25 years old), with confirmed relapsed or refractory ALL. This population can be divided into six subpopulations, including patients who:Have experienced a second or greater bone marrow relapse; ORHave experienced any bone marrow relapse following allogenic stem cell transplant (SCT); ORAre primary refractory, as defined by not achieving a complete response after two cycles of a standard chemotherapy regimen; ORAre chemo refractory, as defined by not achieving a complete response after one cycle of standard chemotherapy for relapsed leukaemia; ORAre Philadelphia chromosome positive AND are intolerant to or have failed two lines of tyrosine kinase inhibitor therapy, OR for whom such therapy is contraindicated; ORAre ineligible for allogenic SCT because of comorbid disease, contraindications to the conditioning regimen, prior SCT, OR lack of a suitable donor.This is the same indication that will be sought from the Therapeutic Goods Administration (TGA). Tisagenlecleucel (the proposed service) was approved by the Food and Drug Administration (FDA) in August 2017 and was the first chimeric antigen receptor T cell therapy approved in the US for the treatment of refractory or relapsed B-cell precursor ALL in patients up to age 25 years. REDACTEDPopulation 2: relapsed or refractory diffuse large B-cell lymphoma (DLBCL) The applicant proposes the medical service should also be intended for adult patients (≥18 years) with confirmed relapsed or refractory DLBCL. This means patients who have relapsed or refractory disease after at least two lines of chemotherapy, and (1) have relapsed after autologous SCT, or (2) are ineligible for subsequent SCT. These criteria would create five eligible sub-populations:DLBCL patients who are refractory or relapsed after:Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (RCHOP) and salvage chemotherapyRCHOP and high-dose therapy (HDT)RCHOP, autologous SCT and salvage chemotherapyRCHOP, autologous SCT and HDT (without response/SCT)RCHOP, autologous SCT and HDT (with subsequent response and subsequent SCT)DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL), responsible for around 25% of NHL cases. The average age of DLBCL diagnosis is 60-65 years, with the likelihood of receiving a diagnosis increasing with age, however it can occur at any age. The applicant states the estimated incidence of DLBCL in Australia is around 2,070 patients per year, and reports that approximately 60% of patients with DLBCL achieve and maintain complete remission after first-line therapy. This means around 40% of patients have incomplete response to therapy, with approximately 10% suffering from refractory disease and 30% having a relapse. AIHW figures show relative 1-year and 5-year survival from DLBCL in Australia was 77.3% (95%CI 75.8-78.8%) and 64.4% (95%CI 62.7-66.1%), respectively (AIHW Australian Cancer database, 2006-2010). In 2011, 4,631 people were diagnosed with NHL. 2.1.1 Rationale / evidence baseThe applicant referred to three published studies on the proposed service which included ALL patients PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaXR6Z2VyYWxkPC9BdXRob3I+PFllYXI+MjAxNzwvWWVh

cj48UmVjTnVtPjQ8L1JlY051bT48SURUZXh0PmUxMjQtZTEzMTwvSURUZXh0PjxEaXNwbGF5VGV4

dD4oRml0emdlcmFsZCBldCBhbC4gMjAxNzsgTWF1ZGUgZXQgYWwuIDIwMTQ7IE11ZWxsZXIgZXQg

YWwuIDIwMTcpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjQ8L3JlYy1udW1iZXI+

PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJmZmVzemV3MnA1ZjBmOGUwZGY1cHQ1

ZHdwZjlmOTJzMHZhZHciIHRpbWVzdGFtcD0iMTUxNTU0NTYzNiI+NDwva2V5PjwvZm9yZWlnbi1r

ZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJp

YnV0b3JzPjxhdXRob3JzPjxhdXRob3I+Rml0emdlcmFsZCwgSi4gQy48L2F1dGhvcj48YXV0aG9y

PldlaXNzLCBTLiBMLjwvYXV0aG9yPjxhdXRob3I+TWF1ZGUsIFMuIEwuPC9hdXRob3I+PGF1dGhv

cj5CYXJyZXR0LCBELiBNLjwvYXV0aG9yPjxhdXRob3I+TGFjZXksIFMuIEYuPC9hdXRob3I+PGF1

dGhvcj5NZWxlbmhvcnN0LCBKLiBKLjwvYXV0aG9yPjxhdXRob3I+U2hhdywgUC48L2F1dGhvcj48

YXV0aG9yPkJlcmcsIFIuIEEuPC9hdXRob3I+PGF1dGhvcj5KdW5lLCBDLiBILjwvYXV0aG9yPjxh

dXRob3I+UG9ydGVyLCBELiBMLjwvYXV0aG9yPjxhdXRob3I+RnJleSwgTi4gVi48L2F1dGhvcj48

YXV0aG9yPkdydXBwLCBTLiBBLjwvYXV0aG9yPjxhdXRob3I+VGVhY2hleSwgRC4gVC48L2F1dGhv

cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz4xRGl2aXNpb24gb2YgQ3Jp

dGljYWwgQ2FyZSBNZWRpY2luZSwgRGVwYXJ0bWVudCBvZiBBbmVzdGhlc2lhIGFuZCBDcml0aWNh

bCBDYXJlLCBUaGUgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsIG9mIFBoaWxhZGVscGhpYSBhbmQg

VGhlIFVuaXZlcnNpdHkgb2YgUGVubnN5bHZhbmlhIFBlcmVsbWFuIFNjaG9vbCBvZiBNZWRpY2lu

ZSwgUGhpbGFkZWxwaGlhLCBQQS4gMkRpdmlzaW9uIG9mIE9uY29sb2d5LCBEZXBhcnRtZW50IG9m

IFBlZGlhdHJpY3MsIFRoZSBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWwgb2YgUGhpbGFkZWxwaGlh

IGFuZCBUaGUgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgUGVyZWxtYW4gU2Nob29sIG9mIE1l

ZGljaW5lLCBQaGlsYWRlbHBoaWEsIFBBLiAzQ2VudGVyIGZvciBDZWxsdWxhciBJbW11bm90aGVy

YXBpZXMsIERlcGFydG1lbnQgb2YgUGF0aG9sb2d5IGFuZCBMYWJvcmF0b3J5IE1lZGljaW5lLCBU

aGUgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgUGVyZWxtYW4gU2Nob29sIG9mIE1lZGljaW5l

LCBQaGlsYWRlbHBoaWEsIFBBLiA0RGVwYXJ0bWVudCBvZiBCaW9zdGF0aXN0aWNzIGFuZCBFcGlk

ZW1pb2xvZ3ksIFRoZSBVbml2ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSBQZXJlbG1hbiBTY2hvb2wg

b2YgTWVkaWNpbmUsIFBoaWxhZGVscGhpYSwgUEEuIDVEaXZpc2lvbiBvZiBIZW1hdG9sb2d5LU9u

Y29sb2d5LCBEZXBhcnRtZW50IG9mIE1lZGljaW5lLCBBYnJhbXNvbiBDYW5jZXIgQ2VudGVyLCBU

aGUgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgUGVyZWxtYW4gU2Nob29sIG9mIE1lZGljaW5l

LCBQaGlsYWRlbHBoaWEsIFBBLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkN5dG9raW5l

IFJlbGVhc2UgU3luZHJvbWUgQWZ0ZXIgQ2hpbWVyaWMgQW50aWdlbiBSZWNlcHRvciBUIENlbGwg

VGhlcmFweSBmb3IgQWN1dGUgTHltcGhvYmxhc3RpYyBMZXVrZW1pYTwvdGl0bGU+PHNlY29uZGFy

eS10aXRsZT5Dcml0IENhcmUgTWVkPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+Q3JpdCBDYXJlIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBh

Z2VzPmUxMjQtZTEzMTwvcGFnZXM+PHZvbHVtZT40NTwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVy

PjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFudGlib2Rp

ZXMsIE1vbm9jbG9uYWwsIEh1bWFuaXplZC90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdv

cmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQsIFByZXNjaG9vbDwva2V5d29yZD48a2V5

d29yZD5DeXRva2luZXMvKm1ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2JsYXN0aWMgTGV1a2VtaWEtTHltcGhvbWEvKmRydWcg

dGhlcmFweS9pbW11bm9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlJlY2VwdG9ycywgQW50aWdlbiwg

VC1DZWxsL2ltbXVub2xvZ3kvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5SZWNv

bWJpbmFudCBGdXNpb24gUHJvdGVpbnMvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3Jk

PlJlY3VycmVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+UmV0cm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3

b3JkPjxrZXl3b3JkPlN5bmRyb21lPC9rZXl3b3JkPjxrZXl3b3JkPlN5c3RlbWljIEluZmxhbW1h

dG9yeSBSZXNwb25zZSBTeW5kcm9tZS8qY2hlbWljYWxseSBpbmR1Y2VkPC9rZXl3b3JkPjxrZXl3

b3JkPllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTc8L3ll

YXI+PHB1Yi1kYXRlcz48ZGF0ZT5GZWI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4x

NTMwLTAyOTMgKEVsZWN0cm9uaWMpJiN4RDswMDkwLTM0OTMgKExpbmtpbmcpPC9pc2JuPjxhY2Nl

c3Npb24tbnVtPjI3NjMyNjgwPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVy

bD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI3NjMyNjgwPC91cmw+PHVybD5o

dHRwOi8vb3ZpZHNwLnR4Lm92aWQuY29tL292ZnRwZGZzL0ZQREROQ0lCUEdQT0dCMDAvZnMwNDcv

b3ZmdC9saXZlL2d2MDI0LzAwMDAzMjQ2LzAwMDAzMjQ2LTIwMTcwMjAwMC0wMDAzNy5wZGY8L3Vy

bD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+NTQ1Mjk4MzwvY3VzdG9tMj48ZWxlY3Ry

b25pYy1yZXNvdXJjZS1udW0+MTAuMTA5Ny9DQ00uMDAwMDAwMDAwMDAwMjA1MzwvZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+TWF1ZGU8L0F1dGhv

cj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNOdW0+MzwvUmVjTnVtPjxJRFRleHQ+MTUwNy0xNzwvSURU

ZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkg

YXBwPSJFTiIgZGItaWQ9ImZmZXN6ZXcycDVmMGY4ZTBkZjVwdDVkd3BmOWY5MnMwdmFkdyIgdGlt

ZXN0YW1wPSIxNTE1NTQ0ODY5Ij4zPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9

IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1

dGhvcj5NYXVkZSwgUy4gTC48L2F1dGhvcj48YXV0aG9yPkZyZXksIE4uPC9hdXRob3I+PGF1dGhv

cj5TaGF3LCBQLiBBLjwvYXV0aG9yPjxhdXRob3I+QXBsZW5jLCBSLjwvYXV0aG9yPjxhdXRob3I+

QmFycmV0dCwgRC4gTS48L2F1dGhvcj48YXV0aG9yPkJ1bmluLCBOLiBKLjwvYXV0aG9yPjxhdXRo

b3I+Q2hldywgQS48L2F1dGhvcj48YXV0aG9yPkdvbnphbGV6LCBWLiBFLjwvYXV0aG9yPjxhdXRo

b3I+WmhlbmcsIFouPC9hdXRob3I+PGF1dGhvcj5MYWNleSwgUy4gRi48L2F1dGhvcj48YXV0aG9y

Pk1haG5rZSwgWS4gRC48L2F1dGhvcj48YXV0aG9yPk1lbGVuaG9yc3QsIEouIEouPC9hdXRob3I+

PGF1dGhvcj5SaGVpbmdvbGQsIFMuIFIuPC9hdXRob3I+PGF1dGhvcj5TaGVuLCBBLjwvYXV0aG9y

PjxhdXRob3I+VGVhY2hleSwgRC4gVC48L2F1dGhvcj48YXV0aG9yPkxldmluZSwgQi4gTC48L2F1

dGhvcj48YXV0aG9yPkp1bmUsIEMuIEguPC9hdXRob3I+PGF1dGhvcj5Qb3J0ZXIsIEQuIEwuPC9h

dXRob3I+PGF1dGhvcj5HcnVwcCwgUy4gQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRv

cnM+PGF1dGgtYWRkcmVzcz5Gcm9tIHRoZSBEaXZpc2lvbiBvZiBPbmNvbG9neSwgQ2hpbGRyZW4m

YXBvcztzIEhvc3BpdGFsIG9mIFBoaWxhZGVscGhpYSAoUy5MLk0uLCBSLkEuLCBELk0uQi4sIE4u

Si5CLiwgUy5SLlIuLCBELlQuVC4sIFMuQS5HLiksIHRoZSBEZXBhcnRtZW50cyBvZiBQZWRpYXRy

aWNzIChTLkwuTS4sIFIuQS4sIEQuTS5CLiwgTi5KLkIuLCBTLlIuUi4sIEQuVC5ULiwgUy5BLkcu

KSwgQmlvc3RhdGlzdGljcyBhbmQgRXBpZGVtaW9sb2d5IChQLkEuUy4sIFIuQS4pLCBhbmQgUGF0

aG9sb2d5IGFuZCBMYWJvcmF0b3J5IE1lZGljaW5lIChKLkouTS4sIEIuTC5MLiwgQy5ILkouLCBT

LkEuRy4pLCB0aGUgRGl2aXNpb24gb2YgSGVtYXRvbG9neS1PbmNvbG9neSAoTi5GLiwgRC5MLlAu

KSwgYW5kIEFicmFtc29uIENhbmNlciBDZW50ZXIgKE4uRi4sIEEuQy4sIFYuRS5HLiwgWi5aLiwg

Uy5GLkwuLCBZLkQuTS4sIEouSi5NLiwgQi5MLkwuLCBDLkguSi4sIEQuTC5QLiwgUy5BLkcuKSwg

UGVyZWxtYW4gU2Nob29sIG9mIE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSAt

IGFsbCBpbiBQaGlsYWRlbHBoaWE7IGFuZCBOb3ZhcnRpcyBQaGFybWFjZXV0aWNhbHMsIEVhc3Qg

SGFub3ZlciwgTkogKEEuUy4pLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNoaW1lcmlj

IGFudGlnZW4gcmVjZXB0b3IgVCBjZWxscyBmb3Igc3VzdGFpbmVkIHJlbWlzc2lvbnMgaW4gbGV1

a2VtaWE8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+TiBFbmdsIEogTWVkPC9zZWNvbmRhcnktdGl0

bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TiBFbmdsIEogTWVkPC9mdWxsLXRp

dGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MTUwNy0xNzwvcGFnZXM+PHZvbHVtZT4zNzE8L3ZvbHVt

ZT48bnVtYmVyPjE2PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdv

cmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aWJvZGllcywgTW9ub2Nsb25h

bCwgSHVtYW5pemVkL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD4qQW50aWdlbnMs

IENEMTk8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQsIFBy

ZXNjaG9vbDwva2V5d29yZD48a2V5d29yZD5DaGltZXJhPC9rZXl3b3JkPjxrZXl3b3JkPkN5dG9r

aW5lcy9ibG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2Vu

ZXRpYyBFbmdpbmVlcmluZzwva2V5d29yZD48a2V5d29yZD4qR2VuZXRpYyBUaGVyYXB5PC9rZXl3

b3JkPjxrZXl3b3JkPkdlbmV0aWMgVmVjdG9yczwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tl

eXdvcmQ+PGtleXdvcmQ+KkltbXVub3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+TGVudGl2aXJ1

cy9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRs

ZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2JsYXN0aWMgTGV1

a2VtaWEtTHltcGhvbWEvaW1tdW5vbG9neS9tb3J0YWxpdHkvKnRoZXJhcHk8L2tleXdvcmQ+PGtl

eXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvZ2VuZXRpY3MvKnRoZXJhcGV1dGljIHVz

ZTwva2V5d29yZD48a2V5d29yZD5SZWN1cnJlbmNlPC9rZXl3b3JkPjxrZXl3b3JkPlJlbWlzc2lv

biBJbmR1Y3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgUmF0ZTwva2V5d29yZD48a2V5

d29yZD5ULUx5bXBob2N5dGVzLyppbW11bm9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPllvdW5nIEFk

dWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PHB1Yi1kYXRl

cz48ZGF0ZT5PY3QgMTY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTMzLTQ0MDYg

KEVsZWN0cm9uaWMpJiN4RDswMDI4LTQ3OTMgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVt

PjI1MzE3ODcwPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8v

d3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI1MzE3ODcwPC91cmw+PHVybD5odHRwOi8vd3d3

Lm5lam0ub3JnL2RvaS9wZGYvMTAuMTA1Ni9ORUpNb2ExNDA3MjIyPC91cmw+PC9yZWxhdGVkLXVy

bHM+PC91cmxzPjxjdXN0b20yPjQyNjc1MzE8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjEwLjEwNTYvTkVKTW9hMTQwNzIyMjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNv

cmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+TXVlbGxlcjwvQXV0aG9yPjxZZWFyPjIwMTc8L1llYXI+

PFJlY051bT4yPC9SZWNOdW0+PElEVGV4dD4yMzE3LTIzMjU8L0lEVGV4dD48cmVjb3JkPjxyZWMt

bnVtYmVyPjI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJm

ZmVzemV3MnA1ZjBmOGUwZGY1cHQ1ZHdwZjlmOTJzMHZhZHciIHRpbWVzdGFtcD0iMTUxNTU0NDc4

MCI+Mjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TXVlbGxlciwgSy4g

VC48L2F1dGhvcj48YXV0aG9yPk1hdWRlLCBTLiBMLjwvYXV0aG9yPjxhdXRob3I+UG9ydGVyLCBE

LiBMLjwvYXV0aG9yPjxhdXRob3I+RnJleSwgTi48L2F1dGhvcj48YXV0aG9yPldvb2QsIFAuPC9h

dXRob3I+PGF1dGhvcj5IYW4sIFguPC9hdXRob3I+PGF1dGhvcj5XYWxkcm9uLCBFLjwvYXV0aG9y

PjxhdXRob3I+Q2hha3JhYm9ydHksIEEuPC9hdXRob3I+PGF1dGhvcj5Bd2FzdGhpLCBSLjwvYXV0

aG9yPjxhdXRob3I+TGV2aW5lLCBCLiBMLjwvYXV0aG9yPjxhdXRob3I+TWVsZW5ob3JzdCwgSi4g

Si48L2F1dGhvcj48YXV0aG9yPkdydXBwLCBTLiBBLjwvYXV0aG9yPjxhdXRob3I+SnVuZSwgQy4g

SC48L2F1dGhvcj48YXV0aG9yPkxhY2V5LCBTLiBGLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48YXV0aC1hZGRyZXNzPk5vdmFydGlzIFBoYXJtYWNldXRpY2FscyBDb3Jwb3JhdGlv

biwgRWFzdCBIYW5vdmVyLCBOSi4mI3hEO0RpdmlzaW9uIG9mIE9uY29sb2d5LCBDaGlsZHJlbiZh

cG9zO3MgSG9zcGl0YWwgb2YgUGhpbGFkZWxwaGlhLCBQaGlsYWRlbHBoaWEsIFBBOyBhbmQuJiN4

RDtBYnJhbXNvbiBDYW5jZXIgQ2VudGVyLCBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFVu

aXZlcnNpdHkgb2YgUGVubnN5bHZhbmlhLCBQaGlsYWRlbHBoaWEsIFBBLjwvYXV0aC1hZGRyZXNz

Pjx0aXRsZXM+PHRpdGxlPkNlbGx1bGFyIGtpbmV0aWNzIG9mIENUTDAxOSBpbiByZWxhcHNlZC9y

ZWZyYWN0b3J5IEItY2VsbCBhY3V0ZSBseW1waG9ibGFzdGljIGxldWtlbWlhIGFuZCBjaHJvbmlj

IGx5bXBob2N5dGljIGxldWtlbWlhPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkJsb29kPC9zZWNv

bmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Qmxvb2Q8L2Z1bGwt

dGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4yMzE3LTIzMjU8L3BhZ2VzPjx2b2x1bWU+MTMwPC92

b2x1bWU+PG51bWJlcj4yMTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9r

ZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtl

eXdvcmQ+QW50aWJvZGllcywgTW9ub2Nsb25hbCwgSHVtYW5pemVkL3BoYXJtYWNvbG9neS90aGVy

YXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+Qm9uZSBNYXJyb3cgQ2VsbHMvZHJ1ZyBlZmZl

Y3RzL21ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBQcm9saWZlcmF0aW9uL2RydWcg

ZWZmZWN0czwva2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48a2V5d29yZD5DaGlsZCwg

UHJlc2Nob29sPC9rZXl3b3JkPjxrZXl3b3JkPkN5dG9raW5lcy9ibG9vZDwva2V5d29yZD48a2V5

d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SW5mYW50PC9rZXl3b3JkPjxrZXl3b3JkPktp

bmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkxldWtlbWlhLCBMeW1waG9jeXRpYywgQ2hyb25pYywg

Qi1DZWxsL2Jsb29kL2RydWcgdGhlcmFweS8qcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1p

ZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2JsYXN0aWMg

TGV1a2VtaWEtTHltcGhvbWEvYmxvb2QvZHJ1ZyB0aGVyYXB5LypwYXRob2xvZ3k8L2tleXdvcmQ+

PGtleXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvKm1ldGFib2xpc208L2tleXdvcmQ+

PGtleXdvcmQ+UmVjdXJyZW5jZTwva2V5d29yZD48a2V5d29yZD5UcmFuc2dlbmVzPC9rZXl3b3Jk

PjxrZXl3b3JkPlR1bW9yIEJ1cmRlbi9kcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+WW91

bmcgQWR1bHQ8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNzwveWVhcj48cHVi

LWRhdGVzPjxkYXRlPk5vdiAyMzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE1Mjgt

MDAyMCAoRWxlY3Ryb25pYykmI3hEOzAwMDYtNDk3MSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lv

bi1udW0+Mjg5MzU2OTQ8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0

dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjg5MzU2OTQ8L3VybD48dXJsPmh0dHA6

Ly93d3cuYmxvb2Rqb3VybmFsLm9yZy9jb250ZW50L2Jsb29kam91cm5hbC8xMzAvMjEvMjMxNy5m

dWxsLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1u

dW0+MTAuMTE4Mi9ibG9vZC0yMDE3LTA2LTc4NjEyOTwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+

PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaXR6Z2VyYWxkPC9BdXRob3I+PFllYXI+MjAxNzwvWWVh

cj48UmVjTnVtPjQ8L1JlY051bT48SURUZXh0PmUxMjQtZTEzMTwvSURUZXh0PjxEaXNwbGF5VGV4

dD4oRml0emdlcmFsZCBldCBhbC4gMjAxNzsgTWF1ZGUgZXQgYWwuIDIwMTQ7IE11ZWxsZXIgZXQg

YWwuIDIwMTcpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjQ8L3JlYy1udW1iZXI+

PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJmZmVzemV3MnA1ZjBmOGUwZGY1cHQ1

ZHdwZjlmOTJzMHZhZHciIHRpbWVzdGFtcD0iMTUxNTU0NTYzNiI+NDwva2V5PjwvZm9yZWlnbi1r

ZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJp

YnV0b3JzPjxhdXRob3JzPjxhdXRob3I+Rml0emdlcmFsZCwgSi4gQy48L2F1dGhvcj48YXV0aG9y

PldlaXNzLCBTLiBMLjwvYXV0aG9yPjxhdXRob3I+TWF1ZGUsIFMuIEwuPC9hdXRob3I+PGF1dGhv

cj5CYXJyZXR0LCBELiBNLjwvYXV0aG9yPjxhdXRob3I+TGFjZXksIFMuIEYuPC9hdXRob3I+PGF1

dGhvcj5NZWxlbmhvcnN0LCBKLiBKLjwvYXV0aG9yPjxhdXRob3I+U2hhdywgUC48L2F1dGhvcj48

YXV0aG9yPkJlcmcsIFIuIEEuPC9hdXRob3I+PGF1dGhvcj5KdW5lLCBDLiBILjwvYXV0aG9yPjxh

dXRob3I+UG9ydGVyLCBELiBMLjwvYXV0aG9yPjxhdXRob3I+RnJleSwgTi4gVi48L2F1dGhvcj48

YXV0aG9yPkdydXBwLCBTLiBBLjwvYXV0aG9yPjxhdXRob3I+VGVhY2hleSwgRC4gVC48L2F1dGhv

cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz4xRGl2aXNpb24gb2YgQ3Jp

dGljYWwgQ2FyZSBNZWRpY2luZSwgRGVwYXJ0bWVudCBvZiBBbmVzdGhlc2lhIGFuZCBDcml0aWNh

bCBDYXJlLCBUaGUgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsIG9mIFBoaWxhZGVscGhpYSBhbmQg

VGhlIFVuaXZlcnNpdHkgb2YgUGVubnN5bHZhbmlhIFBlcmVsbWFuIFNjaG9vbCBvZiBNZWRpY2lu

ZSwgUGhpbGFkZWxwaGlhLCBQQS4gMkRpdmlzaW9uIG9mIE9uY29sb2d5LCBEZXBhcnRtZW50IG9m

IFBlZGlhdHJpY3MsIFRoZSBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWwgb2YgUGhpbGFkZWxwaGlh

IGFuZCBUaGUgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgUGVyZWxtYW4gU2Nob29sIG9mIE1l

ZGljaW5lLCBQaGlsYWRlbHBoaWEsIFBBLiAzQ2VudGVyIGZvciBDZWxsdWxhciBJbW11bm90aGVy

YXBpZXMsIERlcGFydG1lbnQgb2YgUGF0aG9sb2d5IGFuZCBMYWJvcmF0b3J5IE1lZGljaW5lLCBU

aGUgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgUGVyZWxtYW4gU2Nob29sIG9mIE1lZGljaW5l

LCBQaGlsYWRlbHBoaWEsIFBBLiA0RGVwYXJ0bWVudCBvZiBCaW9zdGF0aXN0aWNzIGFuZCBFcGlk

ZW1pb2xvZ3ksIFRoZSBVbml2ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSBQZXJlbG1hbiBTY2hvb2wg

b2YgTWVkaWNpbmUsIFBoaWxhZGVscGhpYSwgUEEuIDVEaXZpc2lvbiBvZiBIZW1hdG9sb2d5LU9u

Y29sb2d5LCBEZXBhcnRtZW50IG9mIE1lZGljaW5lLCBBYnJhbXNvbiBDYW5jZXIgQ2VudGVyLCBU

aGUgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgUGVyZWxtYW4gU2Nob29sIG9mIE1lZGljaW5l

LCBQaGlsYWRlbHBoaWEsIFBBLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkN5dG9raW5l

IFJlbGVhc2UgU3luZHJvbWUgQWZ0ZXIgQ2hpbWVyaWMgQW50aWdlbiBSZWNlcHRvciBUIENlbGwg

VGhlcmFweSBmb3IgQWN1dGUgTHltcGhvYmxhc3RpYyBMZXVrZW1pYTwvdGl0bGU+PHNlY29uZGFy

eS10aXRsZT5Dcml0IENhcmUgTWVkPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+Q3JpdCBDYXJlIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBh

Z2VzPmUxMjQtZTEzMTwvcGFnZXM+PHZvbHVtZT40NTwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVy

PjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFudGlib2Rp

ZXMsIE1vbm9jbG9uYWwsIEh1bWFuaXplZC90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdv

cmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQsIFByZXNjaG9vbDwva2V5d29yZD48a2V5

d29yZD5DeXRva2luZXMvKm1ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2JsYXN0aWMgTGV1a2VtaWEtTHltcGhvbWEvKmRydWcg

dGhlcmFweS9pbW11bm9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlJlY2VwdG9ycywgQW50aWdlbiwg

VC1DZWxsL2ltbXVub2xvZ3kvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5SZWNv

bWJpbmFudCBGdXNpb24gUHJvdGVpbnMvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3Jk

PlJlY3VycmVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+UmV0cm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3

b3JkPjxrZXl3b3JkPlN5bmRyb21lPC9rZXl3b3JkPjxrZXl3b3JkPlN5c3RlbWljIEluZmxhbW1h

dG9yeSBSZXNwb25zZSBTeW5kcm9tZS8qY2hlbWljYWxseSBpbmR1Y2VkPC9rZXl3b3JkPjxrZXl3

b3JkPllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTc8L3ll

YXI+PHB1Yi1kYXRlcz48ZGF0ZT5GZWI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4x

NTMwLTAyOTMgKEVsZWN0cm9uaWMpJiN4RDswMDkwLTM0OTMgKExpbmtpbmcpPC9pc2JuPjxhY2Nl

c3Npb24tbnVtPjI3NjMyNjgwPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVy

bD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI3NjMyNjgwPC91cmw+PHVybD5o

dHRwOi8vb3ZpZHNwLnR4Lm92aWQuY29tL292ZnRwZGZzL0ZQREROQ0lCUEdQT0dCMDAvZnMwNDcv

b3ZmdC9saXZlL2d2MDI0LzAwMDAzMjQ2LzAwMDAzMjQ2LTIwMTcwMjAwMC0wMDAzNy5wZGY8L3Vy

bD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+NTQ1Mjk4MzwvY3VzdG9tMj48ZWxlY3Ry

b25pYy1yZXNvdXJjZS1udW0+MTAuMTA5Ny9DQ00uMDAwMDAwMDAwMDAwMjA1MzwvZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+TWF1ZGU8L0F1dGhv

cj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNOdW0+MzwvUmVjTnVtPjxJRFRleHQ+MTUwNy0xNzwvSURU

ZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkg

YXBwPSJFTiIgZGItaWQ9ImZmZXN6ZXcycDVmMGY4ZTBkZjVwdDVkd3BmOWY5MnMwdmFkdyIgdGlt

ZXN0YW1wPSIxNTE1NTQ0ODY5Ij4zPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9

IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1

dGhvcj5NYXVkZSwgUy4gTC48L2F1dGhvcj48YXV0aG9yPkZyZXksIE4uPC9hdXRob3I+PGF1dGhv

cj5TaGF3LCBQLiBBLjwvYXV0aG9yPjxhdXRob3I+QXBsZW5jLCBSLjwvYXV0aG9yPjxhdXRob3I+

QmFycmV0dCwgRC4gTS48L2F1dGhvcj48YXV0aG9yPkJ1bmluLCBOLiBKLjwvYXV0aG9yPjxhdXRo

b3I+Q2hldywgQS48L2F1dGhvcj48YXV0aG9yPkdvbnphbGV6LCBWLiBFLjwvYXV0aG9yPjxhdXRo

b3I+WmhlbmcsIFouPC9hdXRob3I+PGF1dGhvcj5MYWNleSwgUy4gRi48L2F1dGhvcj48YXV0aG9y

Pk1haG5rZSwgWS4gRC48L2F1dGhvcj48YXV0aG9yPk1lbGVuaG9yc3QsIEouIEouPC9hdXRob3I+

PGF1dGhvcj5SaGVpbmdvbGQsIFMuIFIuPC9hdXRob3I+PGF1dGhvcj5TaGVuLCBBLjwvYXV0aG9y

PjxhdXRob3I+VGVhY2hleSwgRC4gVC48L2F1dGhvcj48YXV0aG9yPkxldmluZSwgQi4gTC48L2F1

dGhvcj48YXV0aG9yPkp1bmUsIEMuIEguPC9hdXRob3I+PGF1dGhvcj5Qb3J0ZXIsIEQuIEwuPC9h

dXRob3I+PGF1dGhvcj5HcnVwcCwgUy4gQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRv

cnM+PGF1dGgtYWRkcmVzcz5Gcm9tIHRoZSBEaXZpc2lvbiBvZiBPbmNvbG9neSwgQ2hpbGRyZW4m

YXBvcztzIEhvc3BpdGFsIG9mIFBoaWxhZGVscGhpYSAoUy5MLk0uLCBSLkEuLCBELk0uQi4sIE4u

Si5CLiwgUy5SLlIuLCBELlQuVC4sIFMuQS5HLiksIHRoZSBEZXBhcnRtZW50cyBvZiBQZWRpYXRy

aWNzIChTLkwuTS4sIFIuQS4sIEQuTS5CLiwgTi5KLkIuLCBTLlIuUi4sIEQuVC5ULiwgUy5BLkcu

KSwgQmlvc3RhdGlzdGljcyBhbmQgRXBpZGVtaW9sb2d5IChQLkEuUy4sIFIuQS4pLCBhbmQgUGF0

aG9sb2d5IGFuZCBMYWJvcmF0b3J5IE1lZGljaW5lIChKLkouTS4sIEIuTC5MLiwgQy5ILkouLCBT

LkEuRy4pLCB0aGUgRGl2aXNpb24gb2YgSGVtYXRvbG9neS1PbmNvbG9neSAoTi5GLiwgRC5MLlAu

KSwgYW5kIEFicmFtc29uIENhbmNlciBDZW50ZXIgKE4uRi4sIEEuQy4sIFYuRS5HLiwgWi5aLiwg

Uy5GLkwuLCBZLkQuTS4sIEouSi5NLiwgQi5MLkwuLCBDLkguSi4sIEQuTC5QLiwgUy5BLkcuKSwg

UGVyZWxtYW4gU2Nob29sIG9mIE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSAt

IGFsbCBpbiBQaGlsYWRlbHBoaWE7IGFuZCBOb3ZhcnRpcyBQaGFybWFjZXV0aWNhbHMsIEVhc3Qg

SGFub3ZlciwgTkogKEEuUy4pLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNoaW1lcmlj

IGFudGlnZW4gcmVjZXB0b3IgVCBjZWxscyBmb3Igc3VzdGFpbmVkIHJlbWlzc2lvbnMgaW4gbGV1

a2VtaWE8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+TiBFbmdsIEogTWVkPC9zZWNvbmRhcnktdGl0

bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TiBFbmdsIEogTWVkPC9mdWxsLXRp

dGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MTUwNy0xNzwvcGFnZXM+PHZvbHVtZT4zNzE8L3ZvbHVt

ZT48bnVtYmVyPjE2PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdv

cmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aWJvZGllcywgTW9ub2Nsb25h

bCwgSHVtYW5pemVkL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD4qQW50aWdlbnMs

IENEMTk8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQsIFBy

ZXNjaG9vbDwva2V5d29yZD48a2V5d29yZD5DaGltZXJhPC9rZXl3b3JkPjxrZXl3b3JkPkN5dG9r

aW5lcy9ibG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2Vu

ZXRpYyBFbmdpbmVlcmluZzwva2V5d29yZD48a2V5d29yZD4qR2VuZXRpYyBUaGVyYXB5PC9rZXl3

b3JkPjxrZXl3b3JkPkdlbmV0aWMgVmVjdG9yczwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tl

eXdvcmQ+PGtleXdvcmQ+KkltbXVub3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+TGVudGl2aXJ1

cy9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRs

ZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2JsYXN0aWMgTGV1

a2VtaWEtTHltcGhvbWEvaW1tdW5vbG9neS9tb3J0YWxpdHkvKnRoZXJhcHk8L2tleXdvcmQ+PGtl

eXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvZ2VuZXRpY3MvKnRoZXJhcGV1dGljIHVz

ZTwva2V5d29yZD48a2V5d29yZD5SZWN1cnJlbmNlPC9rZXl3b3JkPjxrZXl3b3JkPlJlbWlzc2lv

biBJbmR1Y3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgUmF0ZTwva2V5d29yZD48a2V5

d29yZD5ULUx5bXBob2N5dGVzLyppbW11bm9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPllvdW5nIEFk

dWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PHB1Yi1kYXRl

cz48ZGF0ZT5PY3QgMTY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTMzLTQ0MDYg

KEVsZWN0cm9uaWMpJiN4RDswMDI4LTQ3OTMgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVt

PjI1MzE3ODcwPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8v

d3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI1MzE3ODcwPC91cmw+PHVybD5odHRwOi8vd3d3

Lm5lam0ub3JnL2RvaS9wZGYvMTAuMTA1Ni9ORUpNb2ExNDA3MjIyPC91cmw+PC9yZWxhdGVkLXVy

bHM+PC91cmxzPjxjdXN0b20yPjQyNjc1MzE8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjEwLjEwNTYvTkVKTW9hMTQwNzIyMjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNv

cmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+TXVlbGxlcjwvQXV0aG9yPjxZZWFyPjIwMTc8L1llYXI+

PFJlY051bT4yPC9SZWNOdW0+PElEVGV4dD4yMzE3LTIzMjU8L0lEVGV4dD48cmVjb3JkPjxyZWMt

bnVtYmVyPjI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJm

ZmVzemV3MnA1ZjBmOGUwZGY1cHQ1ZHdwZjlmOTJzMHZhZHciIHRpbWVzdGFtcD0iMTUxNTU0NDc4

MCI+Mjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TXVlbGxlciwgSy4g

VC48L2F1dGhvcj48YXV0aG9yPk1hdWRlLCBTLiBMLjwvYXV0aG9yPjxhdXRob3I+UG9ydGVyLCBE

LiBMLjwvYXV0aG9yPjxhdXRob3I+RnJleSwgTi48L2F1dGhvcj48YXV0aG9yPldvb2QsIFAuPC9h

dXRob3I+PGF1dGhvcj5IYW4sIFguPC9hdXRob3I+PGF1dGhvcj5XYWxkcm9uLCBFLjwvYXV0aG9y

PjxhdXRob3I+Q2hha3JhYm9ydHksIEEuPC9hdXRob3I+PGF1dGhvcj5Bd2FzdGhpLCBSLjwvYXV0

aG9yPjxhdXRob3I+TGV2aW5lLCBCLiBMLjwvYXV0aG9yPjxhdXRob3I+TWVsZW5ob3JzdCwgSi4g

Si48L2F1dGhvcj48YXV0aG9yPkdydXBwLCBTLiBBLjwvYXV0aG9yPjxhdXRob3I+SnVuZSwgQy4g

SC48L2F1dGhvcj48YXV0aG9yPkxhY2V5LCBTLiBGLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48YXV0aC1hZGRyZXNzPk5vdmFydGlzIFBoYXJtYWNldXRpY2FscyBDb3Jwb3JhdGlv

biwgRWFzdCBIYW5vdmVyLCBOSi4mI3hEO0RpdmlzaW9uIG9mIE9uY29sb2d5LCBDaGlsZHJlbiZh

cG9zO3MgSG9zcGl0YWwgb2YgUGhpbGFkZWxwaGlhLCBQaGlsYWRlbHBoaWEsIFBBOyBhbmQuJiN4

RDtBYnJhbXNvbiBDYW5jZXIgQ2VudGVyLCBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFVu

aXZlcnNpdHkgb2YgUGVubnN5bHZhbmlhLCBQaGlsYWRlbHBoaWEsIFBBLjwvYXV0aC1hZGRyZXNz

Pjx0aXRsZXM+PHRpdGxlPkNlbGx1bGFyIGtpbmV0aWNzIG9mIENUTDAxOSBpbiByZWxhcHNlZC9y

ZWZyYWN0b3J5IEItY2VsbCBhY3V0ZSBseW1waG9ibGFzdGljIGxldWtlbWlhIGFuZCBjaHJvbmlj

IGx5bXBob2N5dGljIGxldWtlbWlhPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkJsb29kPC9zZWNv

bmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Qmxvb2Q8L2Z1bGwt

dGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4yMzE3LTIzMjU8L3BhZ2VzPjx2b2x1bWU+MTMwPC92

b2x1bWU+PG51bWJlcj4yMTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9r

ZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtl

eXdvcmQ+QW50aWJvZGllcywgTW9ub2Nsb25hbCwgSHVtYW5pemVkL3BoYXJtYWNvbG9neS90aGVy

YXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+Qm9uZSBNYXJyb3cgQ2VsbHMvZHJ1ZyBlZmZl

Y3RzL21ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBQcm9saWZlcmF0aW9uL2RydWcg

ZWZmZWN0czwva2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48a2V5d29yZD5DaGlsZCwg

UHJlc2Nob29sPC9rZXl3b3JkPjxrZXl3b3JkPkN5dG9raW5lcy9ibG9vZDwva2V5d29yZD48a2V5

d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SW5mYW50PC9rZXl3b3JkPjxrZXl3b3JkPktp

bmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkxldWtlbWlhLCBMeW1waG9jeXRpYywgQ2hyb25pYywg

Qi1DZWxsL2Jsb29kL2RydWcgdGhlcmFweS8qcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1p

ZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2JsYXN0aWMg

TGV1a2VtaWEtTHltcGhvbWEvYmxvb2QvZHJ1ZyB0aGVyYXB5LypwYXRob2xvZ3k8L2tleXdvcmQ+

PGtleXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvKm1ldGFib2xpc208L2tleXdvcmQ+

PGtleXdvcmQ+UmVjdXJyZW5jZTwva2V5d29yZD48a2V5d29yZD5UcmFuc2dlbmVzPC9rZXl3b3Jk

PjxrZXl3b3JkPlR1bW9yIEJ1cmRlbi9kcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+WW91

bmcgQWR1bHQ8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNzwveWVhcj48cHVi

LWRhdGVzPjxkYXRlPk5vdiAyMzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE1Mjgt

MDAyMCAoRWxlY3Ryb25pYykmI3hEOzAwMDYtNDk3MSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lv

bi1udW0+Mjg5MzU2OTQ8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0

dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjg5MzU2OTQ8L3VybD48dXJsPmh0dHA6

Ly93d3cuYmxvb2Rqb3VybmFsLm9yZy9jb250ZW50L2Jsb29kam91cm5hbC8xMzAvMjEvMjMxNy5m

dWxsLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1u

dW0+MTAuMTE4Mi9ibG9vZC0yMDE3LTA2LTc4NjEyOTwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+

PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA (Fitzgerald et al. 2017; Maude et al. 2014; Mueller et al. 2017), and one study including DLBCL patients (n=13). A number of studies are still ongoing, on both patients with ALL and DLBCL ADDIN EN.CITE <EndNote><Cite ExcludeAuth="1"><Year>2017</Year><RecNum>6</RecNum><DisplayText>(&apos;Value in Using CAR T Cells for DLBCL&apos; 2017)</DisplayText><record><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1515628212">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title>Value in Using CAR T Cells for DLBCL</title><secondary-title>Cancer Discov</secondary-title></titles><periodical><full-title>Cancer Discov</full-title></periodical><dates><year>2017</year><pub-dates><date>Dec 15</date></pub-dates></dates><isbn>2159-8290 (Electronic)&#xD;2159-8274 (Linking)</isbn><accession-num>29247018</accession-num><urls><related-urls><url>;('Value in Using CAR T Cells for DLBCL' 2017).One retrospective cohort study, Fitzgerald et al., investigated the timing, severity and management of cytokine release syndrome (CRS; an adverse event) in relapsed/refractory ALL patients (n=39). Maude et al (2014) included 25 relapsed ALL patients aged between 5 and 22 years old, and five aged > 25 (three of which had primary refractory disease). The study reported complete remission in 27/30 patients, with a sustained remission with a 6-month event-free survival rate of 67%. The institute for Clinical and Economic Review also recently published a report on the effectiveness and value of CAR-T therapies for B-cell cancers, summarising the evidence ADDIN EN.CITE <EndNote><Cite><Author>Institute for Clinical and Economic Review (ICER)</Author><Year>2017</Year><RecNum>9</RecNum><DisplayText>(Institute for Clinical and Economic Review (ICER) 2017)</DisplayText><record><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1516335195">9</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Institute for Clinical and Economic Review (ICER),.</author></authors></contributors><titles><title>Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value, Draft evidence report</title></titles><dates><year>2017</year><pub-dates><date>December 19,2017</date></pub-dates></dates><publisher>Institute for Clinical and Economic Review,</publisher><urls></urls></record></Cite></EndNote>(Institute for Clinical and Economic Review (ICER) 2017).The study by Mueller et al (2017) included both children and adult patients with ALL and chronic lymphocytic leukaemia (CLL). There is evidence that CAR-T cells can also be used to treat refractory chronic lymphocytic leukaemia (CLL). One study reported that 8/14 patients had a response (57%), with 4 patients going into complete remission and 4 patients obtaining partial remission. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Qb3J0ZXI8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxS

ZWNOdW0+NzwvUmVjTnVtPjxJRFRleHQ+MzAzcmExMzk8L0lEVGV4dD48RGlzcGxheVRleHQ+KFBv

cnRlciBldCBhbC4gMjAxNSk8L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+NzwvcmVj

LW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9ImZmZXN6ZXcycDVmMGY4

ZTBkZjVwdDVkd3BmOWY5MnMwdmFkdyIgdGltZXN0YW1wPSIxNTE2MDczMDc4Ij43PC9rZXk+PC9m

b3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBl

Pjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Qb3J0ZXIsIEQuIEwuPC9hdXRob3I+PGF1

dGhvcj5Id2FuZywgVy4gVC48L2F1dGhvcj48YXV0aG9yPkZyZXksIE4uIFYuPC9hdXRob3I+PGF1

dGhvcj5MYWNleSwgUy4gRi48L2F1dGhvcj48YXV0aG9yPlNoYXcsIFAuIEEuPC9hdXRob3I+PGF1

dGhvcj5Mb3JlbiwgQS4gVy48L2F1dGhvcj48YXV0aG9yPkJhZ2csIEEuPC9hdXRob3I+PGF1dGhv

cj5NYXJjdWNjaSwgSy4gVC48L2F1dGhvcj48YXV0aG9yPlNoZW4sIEEuPC9hdXRob3I+PGF1dGhv

cj5Hb256YWxleiwgVi48L2F1dGhvcj48YXV0aG9yPkFtYnJvc2UsIEQuPC9hdXRob3I+PGF1dGhv

cj5HcnVwcCwgUy4gQS48L2F1dGhvcj48YXV0aG9yPkNoZXcsIEEuPC9hdXRob3I+PGF1dGhvcj5a

aGVuZywgWi48L2F1dGhvcj48YXV0aG9yPk1pbG9uZSwgTS4gQy48L2F1dGhvcj48YXV0aG9yPkxl

dmluZSwgQi4gTC48L2F1dGhvcj48YXV0aG9yPk1lbGVuaG9yc3QsIEouIEouPC9hdXRob3I+PGF1

dGhvcj5KdW5lLCBDLiBILjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1h

ZGRyZXNzPkRpdmlzaW9uIG9mIEhlbWF0b2xvZ3kvT25jb2xvZ3ksIERlcGFydG1lbnQgb2YgTWVk

aWNpbmUsIGFuZCBBYnJhbXNvbiBDYW5jZXIgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFBlbm5zeWx2

YW5pYSBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFBoaWxhZGVscGhpYSwgUEEgMTkxMDQs

IFVTQS4gZGF2aWQucG9ydGVyQHVwaHMudXBlbm4uZWR1IGNqdW5lQGV4Y2hhbmdlLnVwZW5uLmVk

dS4mI3hEO0RlcGFydG1lbnQgb2YgQmlvc3RhdGlzdGljcyBhbmQgRXBpZGVtaW9sb2d5LCBVbml2

ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFBoaWxh

ZGVscGhpYSwgUEEgMTkxMDQsIFVTQS4mI3hEO0RpdmlzaW9uIG9mIEhlbWF0b2xvZ3kvT25jb2xv

Z3ksIERlcGFydG1lbnQgb2YgTWVkaWNpbmUsIGFuZCBBYnJhbXNvbiBDYW5jZXIgQ2VudGVyLCBV

bml2ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFBo

aWxhZGVscGhpYSwgUEEgMTkxMDQsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgUGF0aG9sb2d5IGFu

ZCBMYWJvcmF0b3J5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSBQZXJlbG1h

biBTY2hvb2wgb2YgTWVkaWNpbmUsIFBoaWxhZGVscGhpYSwgUEEgMTkxMDQsIFVTQS4mI3hEO05v

dmFydGlzIFBoYXJtYWNldXRpY2FsIENvcnBvcmF0aW9uLCBPbmUgSGVhbHRoIFBsYXphLCBFYXN0

IEhhbm92ZXIsIE5KIDA3OTM2LCBVU0EuJiN4RDtEaXZpc2lvbiBvZiBPbmNvbG9neSwgRGVwYXJ0

bWVudCBvZiBQZWRpYXRyaWNzLCBUaGUgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsIG9mIFBoaWxh

ZGVscGhpYSwgUGhpbGFkZWxwaGlhLCBQQSAxOTEwNCwgVVNBLiYjeEQ7RGVwYXJ0bWVudCBvZiBQ

YXRob2xvZ3kgYW5kIExhYm9yYXRvcnkgTWVkaWNpbmUsIFVuaXZlcnNpdHkgb2YgUGVubnN5bHZh

bmlhIFBlcmVsbWFuIFNjaG9vbCBvZiBNZWRpY2luZSwgUGhpbGFkZWxwaGlhLCBQQSAxOTEwNCwg

VVNBLiBkYXZpZC5wb3J0ZXJAdXBocy51cGVubi5lZHUgY2p1bmVAZXhjaGFuZ2UudXBlbm4uZWR1

LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNoaW1lcmljIGFudGlnZW4gcmVjZXB0b3Ig

VCBjZWxscyBwZXJzaXN0IGFuZCBpbmR1Y2Ugc3VzdGFpbmVkIHJlbWlzc2lvbnMgaW4gcmVsYXBz

ZWQgcmVmcmFjdG9yeSBjaHJvbmljIGx5bXBob2N5dGljIGxldWtlbWlhPC90aXRsZT48c2Vjb25k

YXJ5LXRpdGxlPlNjaSBUcmFuc2wgTWVkPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+U2NpIFRyYW5zbCBNZWQ8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2Fs

PjxwYWdlcz4zMDNyYTEzOTwvcGFnZXM+PHZvbHVtZT43PC92b2x1bWU+PG51bWJlcj4zMDM8L251

bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5DeXRva2luZXMv

bWV0YWJvbGlzbTwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVt

YW5zPC9rZXl3b3JkPjxrZXl3b3JkPkltbXVub3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+TGV1

a2VtaWEsIEx5bXBob2N5dGljLCBDaHJvbmljLCBCLUNlbGwvKmltbXVub2xvZ3kvdGhlcmFweTwv

a2V5d29yZD48a2V5d29yZD5NYWNyb3BoYWdlIEFjdGl2YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+

TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5SZWNl

cHRvcnMsIEFudGlnZW4sIFQtQ2VsbC8qaW1tdW5vbG9neTwva2V5d29yZD48a2V5d29yZD4qUmVt

aXNzaW9uIEluZHVjdGlvbjwva2V5d29yZD48a2V5d29yZD5ULUx5bXBob2N5dGVzLyppbW11bm9s

b2d5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1Yi1kYXRl

cz48ZGF0ZT5TZXAgMjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE5NDYtNjI0MiAo

RWxlY3Ryb25pYykmI3hEOzE5NDYtNjIzNCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+

MjYzMzM5MzU8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93

d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjYzMzM5MzU8L3VybD48dXJsPmh0dHA6Ly9zdG0u

c2NpZW5jZW1hZy5vcmcvY29udGVudC9zY2l0cmFuc21lZC83LzMwMy8zMDNyYTEzOS5mdWxsLnBk

ZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAu

MTEyNi9zY2l0cmFuc2xtZWQuYWFjNTQxNTwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNv

cmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Qb3J0ZXI8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxS

ZWNOdW0+NzwvUmVjTnVtPjxJRFRleHQ+MzAzcmExMzk8L0lEVGV4dD48RGlzcGxheVRleHQ+KFBv

cnRlciBldCBhbC4gMjAxNSk8L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+NzwvcmVj

LW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9ImZmZXN6ZXcycDVmMGY4

ZTBkZjVwdDVkd3BmOWY5MnMwdmFkdyIgdGltZXN0YW1wPSIxNTE2MDczMDc4Ij43PC9rZXk+PC9m

b3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBl

Pjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Qb3J0ZXIsIEQuIEwuPC9hdXRob3I+PGF1

dGhvcj5Id2FuZywgVy4gVC48L2F1dGhvcj48YXV0aG9yPkZyZXksIE4uIFYuPC9hdXRob3I+PGF1

dGhvcj5MYWNleSwgUy4gRi48L2F1dGhvcj48YXV0aG9yPlNoYXcsIFAuIEEuPC9hdXRob3I+PGF1

dGhvcj5Mb3JlbiwgQS4gVy48L2F1dGhvcj48YXV0aG9yPkJhZ2csIEEuPC9hdXRob3I+PGF1dGhv

cj5NYXJjdWNjaSwgSy4gVC48L2F1dGhvcj48YXV0aG9yPlNoZW4sIEEuPC9hdXRob3I+PGF1dGhv

cj5Hb256YWxleiwgVi48L2F1dGhvcj48YXV0aG9yPkFtYnJvc2UsIEQuPC9hdXRob3I+PGF1dGhv

cj5HcnVwcCwgUy4gQS48L2F1dGhvcj48YXV0aG9yPkNoZXcsIEEuPC9hdXRob3I+PGF1dGhvcj5a

aGVuZywgWi48L2F1dGhvcj48YXV0aG9yPk1pbG9uZSwgTS4gQy48L2F1dGhvcj48YXV0aG9yPkxl

dmluZSwgQi4gTC48L2F1dGhvcj48YXV0aG9yPk1lbGVuaG9yc3QsIEouIEouPC9hdXRob3I+PGF1

dGhvcj5KdW5lLCBDLiBILjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1h

ZGRyZXNzPkRpdmlzaW9uIG9mIEhlbWF0b2xvZ3kvT25jb2xvZ3ksIERlcGFydG1lbnQgb2YgTWVk

aWNpbmUsIGFuZCBBYnJhbXNvbiBDYW5jZXIgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFBlbm5zeWx2

YW5pYSBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFBoaWxhZGVscGhpYSwgUEEgMTkxMDQs

IFVTQS4gZGF2aWQucG9ydGVyQHVwaHMudXBlbm4uZWR1IGNqdW5lQGV4Y2hhbmdlLnVwZW5uLmVk

dS4mI3hEO0RlcGFydG1lbnQgb2YgQmlvc3RhdGlzdGljcyBhbmQgRXBpZGVtaW9sb2d5LCBVbml2

ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFBoaWxh

ZGVscGhpYSwgUEEgMTkxMDQsIFVTQS4mI3hEO0RpdmlzaW9uIG9mIEhlbWF0b2xvZ3kvT25jb2xv

Z3ksIERlcGFydG1lbnQgb2YgTWVkaWNpbmUsIGFuZCBBYnJhbXNvbiBDYW5jZXIgQ2VudGVyLCBV

bml2ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFBo

aWxhZGVscGhpYSwgUEEgMTkxMDQsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgUGF0aG9sb2d5IGFu

ZCBMYWJvcmF0b3J5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSBQZXJlbG1h

biBTY2hvb2wgb2YgTWVkaWNpbmUsIFBoaWxhZGVscGhpYSwgUEEgMTkxMDQsIFVTQS4mI3hEO05v

dmFydGlzIFBoYXJtYWNldXRpY2FsIENvcnBvcmF0aW9uLCBPbmUgSGVhbHRoIFBsYXphLCBFYXN0

IEhhbm92ZXIsIE5KIDA3OTM2LCBVU0EuJiN4RDtEaXZpc2lvbiBvZiBPbmNvbG9neSwgRGVwYXJ0

bWVudCBvZiBQZWRpYXRyaWNzLCBUaGUgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsIG9mIFBoaWxh

ZGVscGhpYSwgUGhpbGFkZWxwaGlhLCBQQSAxOTEwNCwgVVNBLiYjeEQ7RGVwYXJ0bWVudCBvZiBQ

YXRob2xvZ3kgYW5kIExhYm9yYXRvcnkgTWVkaWNpbmUsIFVuaXZlcnNpdHkgb2YgUGVubnN5bHZh

bmlhIFBlcmVsbWFuIFNjaG9vbCBvZiBNZWRpY2luZSwgUGhpbGFkZWxwaGlhLCBQQSAxOTEwNCwg

VVNBLiBkYXZpZC5wb3J0ZXJAdXBocy51cGVubi5lZHUgY2p1bmVAZXhjaGFuZ2UudXBlbm4uZWR1

LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNoaW1lcmljIGFudGlnZW4gcmVjZXB0b3Ig

VCBjZWxscyBwZXJzaXN0IGFuZCBpbmR1Y2Ugc3VzdGFpbmVkIHJlbWlzc2lvbnMgaW4gcmVsYXBz

ZWQgcmVmcmFjdG9yeSBjaHJvbmljIGx5bXBob2N5dGljIGxldWtlbWlhPC90aXRsZT48c2Vjb25k

YXJ5LXRpdGxlPlNjaSBUcmFuc2wgTWVkPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+U2NpIFRyYW5zbCBNZWQ8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2Fs

PjxwYWdlcz4zMDNyYTEzOTwvcGFnZXM+PHZvbHVtZT43PC92b2x1bWU+PG51bWJlcj4zMDM8L251

bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5DeXRva2luZXMv

bWV0YWJvbGlzbTwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVt

YW5zPC9rZXl3b3JkPjxrZXl3b3JkPkltbXVub3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+TGV1

a2VtaWEsIEx5bXBob2N5dGljLCBDaHJvbmljLCBCLUNlbGwvKmltbXVub2xvZ3kvdGhlcmFweTwv

a2V5d29yZD48a2V5d29yZD5NYWNyb3BoYWdlIEFjdGl2YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+

TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5SZWNl

cHRvcnMsIEFudGlnZW4sIFQtQ2VsbC8qaW1tdW5vbG9neTwva2V5d29yZD48a2V5d29yZD4qUmVt

aXNzaW9uIEluZHVjdGlvbjwva2V5d29yZD48a2V5d29yZD5ULUx5bXBob2N5dGVzLyppbW11bm9s

b2d5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1Yi1kYXRl

cz48ZGF0ZT5TZXAgMjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE5NDYtNjI0MiAo

RWxlY3Ryb25pYykmI3hEOzE5NDYtNjIzNCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+

MjYzMzM5MzU8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93

d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjYzMzM5MzU8L3VybD48dXJsPmh0dHA6Ly9zdG0u

c2NpZW5jZW1hZy5vcmcvY29udGVudC9zY2l0cmFuc21lZC83LzMwMy8zMDNyYTEzOS5mdWxsLnBk

ZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAu

MTEyNi9zY2l0cmFuc2xtZWQuYWFjNTQxNTwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNv

cmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA (Porter et al. 2015). Furthermore, another recently published study included both patients with DLBCL (n=23) and follicular lymphoma (n=15). This study reported a complete remission after receiving CTL019 cells (tisagenlecleucel) in 10/14 patients with follicular lymphoma. ADDIN EN.CITE <EndNote><Cite><Author>Schuster</Author><Year>2017</Year><RecNum>5</RecNum><IDText>2545-2554</IDText><DisplayText>(Schuster et al. 2017)</DisplayText><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1515548902">5</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Schuster, S. J.</author><author>Svoboda, J.</author><author>Chong, E. A.</author><author>Nasta, S. D.</author><author>Mato, A. R.</author><author>Anak, O.</author><author>Brogdon, J. L.</author><author>Pruteanu-Malinici, I.</author><author>Bhoj, V.</author><author>Landsburg, D.</author><author>Wasik, M.</author><author>Levine, B. L.</author><author>Lacey, S. F.</author><author>Melenhorst, J. J.</author><author>Porter, D. L.</author><author>June, C. H.</author></authors></contributors><auth-address>From the Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L., J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).</auth-address><titles><title>Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>2545-2554</pages><volume>377</volume><number>26</number><dates><year>2017</year><pub-dates><date>Dec 28</date></pub-dates></dates><isbn>1533-4406 (Electronic)&#xD;0028-4793 (Linking)</isbn><accession-num>29226764</accession-num><urls><related-urls><url>;(Schuster et al. 2017) This suggests CAR-T therapy may potentially be useful for other indications, in addition to ALL and DLBCL. Around 30 trials are currently ongoing on CAR-T therapies, of which the majority are single-arm. Most are recruiting patients with (refractory or relapsed CD19-positive) ALL or DLBCL, however some are also including patients with CLL, small lymphoblastic lymphoma, multiple myeloma, Hodgkin Lymphoma, mantle cell lymphoma, pancreatic cancer, follicular lymphomas or B-cell malignancies in general. Currently there are around 25 trials on which are (or have completed) investigating tisagenlecleucel specifically (studies found for CTL019 and/or CART-19). On May 1, 2018, the FDA (in the US) approved tisagenlecleucel for the treatment of adult patients with relapsed or refractory DLBCL who have relapsed or are ineligible for autologous SCT. In addition, in January 2018 the European Medicines Agency (EMA) has granted accelerated assessment to the Marketing Authorisation Application (MAA) for tisagenlecleucel for the treatment of children and young adults with relapsed or refractory B-cell ALL and adults with relapsed or refractory DLBCL, who are ineligible for ASCT. This means the decision time would be cut from 201 to 150 days in Europe. This assessment is currently in progress.2.3 Prior test (investigative services only - if prior tests are to be included)Patients will be monitored to see whether they have relapsed or refractory disease. A variety of different tests may be done, including blood counts, bone marrow aspiration and biopsy, lumbar puncture, and/or imaging tests (i.e. x-ray, computerised tomography, magnetic resonance imaging, positron emission tomography, ultrasound). 2.4 InterventionTisagenlecleucel (also known as CTL019, and brand name Kymriah?) is an immunocellular cancer therapy using autologous peripheral blood T-cells, extracted using leukapheresis, which are then reprogrammed with a chimeric antigen receptor (CAR) that identifies and destroys CD19-expressing (malignant and non-malignant) cells ADDIN EN.CITE <EndNote><Cite><Author>Novartis</Author><Year>2017</Year><RecNum>13</RecNum><DisplayText>(Novartis 2017)</DisplayText><record><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1518129870">13</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Novartis,.</author></authors></contributors><titles><title>Oncologic drugs advisory committee briefing document. Tisagenlecleucel (CTL019) for the treatment of pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia</title><secondary-title>FDA Advisory Committee Briefing Document</secondary-title></titles><dates><year>2017</year></dates><urls><related-urls><url>;(Novartis 2017). The CD19 antigens are B-cell specific surface antigens expressed in all B-cell lineage malignancies. The CAR consists of a murine single-chain antibody fragment, which recognises CD19. The patient’s own reprogrammed CAR T-cells (CAR-T) are then re-infused into the patient’s body where they target the cancer cells. According to the Drug Information Portal of the United States National Library of Medicine, tisagenlecleucel is: “Allogeneic T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signalling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities.” The 4-1BB co-stimulatory molecule signalling domain enhances activation and signalling after recognition of the CD19-expressing tumour cell, and the inclusion of this domain may increase the antitumor activity. Synonyms used for tisagenlecleucel are: adoptive immunotherapy agent CTL019, Anti-CD19-CAR transduced T cell, CART-19, CTL019, CTL019 CAR T cell, CTL019 CAR T cell therapy agent, Cytotoxic T cell CTL019, Cytotoxic T cell Tisagenlecleucel-T, Kymriah, Tisagenlecleucel-T.Figure SEQ Figure \* ARABIC 2 CAR-T cell therapy infographicSource: application document (image was provided by the applicant)Novartis indicated that in the US, it would charge $US475,000 ($A598,453) for the treatment, custom-made for each?patient. Treatment is intended for single use (with curative intent). However, there has been at least one patient who received two CAR-T cell infusions, after progression of disease ADDIN EN.CITE <EndNote><Cite><Author>Brudno</Author><Year>2018</Year><RecNum>15</RecNum><IDText>31-46</IDText><DisplayText>(Brudno &amp; Kochenderfer 2018)</DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1526008905">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Brudno, J. N.</author><author>Kochenderfer, J. N.</author></authors></contributors><auth-address>Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH Building 10 room 3-3330, Bethesda, Maryland 20892, USA.</auth-address><titles><title>Chimeric antigen receptor T-cell therapies for lymphoma</title><secondary-title>Nat Rev Clin Oncol</secondary-title></titles><periodical><full-title>Nat Rev Clin Oncol</full-title></periodical><pages>31-46</pages><volume>15</volume><number>1</number><keywords><keyword>Antigens, CD19/*immunology</keyword><keyword>Humans</keyword><keyword>Immunotherapy, Adoptive/*methods</keyword><keyword>Ki-1 Antigen/immunology</keyword><keyword>Lymphoma/*therapy</keyword><keyword>Receptors, Antigen, T-Cell/*immunology/therapeutic use</keyword></keywords><dates><year>2018</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1759-4782 (Electronic)&#xD;1759-4774 (Linking)</isbn><accession-num>28857075</accession-num><urls><related-urls><url>;(Brudno & Kochenderfer 2018). There is uncertainty related to whether, in future, there would be pressure to provide one or more subsequent infusions of tisagenlecleucel, and PASC advised that the SBA and MSAC should consider prospectively how this risk might best be managed. A centralised manufacturing facility genetically encodes the T cells to create tisagenlecleucel and is responsible for the modified T cell expansion. The applicant indicated that the centralised facility would most likely be located in the United States of America. The manufacturing process would take around 2 to 3 weeks from leukapheresis to the time the engineered cells are finalised ADDIN EN.CITE <EndNote><Cite><Author>Institute for Clinical and Economic Review (ICER)</Author><Year>2017</Year><RecNum>9</RecNum><DisplayText>(Institute for Clinical and Economic Review (ICER) 2017)</DisplayText><record><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1516335195">9</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Institute for Clinical and Economic Review (ICER),.</author></authors></contributors><titles><title>Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value, Draft evidence report</title></titles><dates><year>2017</year><pub-dates><date>December 19,2017</date></pub-dates></dates><publisher>Institute for Clinical and Economic Review,</publisher><urls></urls></record></Cite></EndNote>(Institute for Clinical and Economic Review (ICER) 2017). REDACTED A recently published study reported a median time from enrolment to infusion of 45 days (range 30 to 105, n=75) PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYXVkZTwvQXV0aG9yPjxZZWFyPjIwMTg8L1llYXI+PFJl

Y051bT4xMjwvUmVjTnVtPjxJRFRleHQ+NDM5LTQ0ODwvSURUZXh0PjxEaXNwbGF5VGV4dD4oTWF1

ZGUgZXQgYWwuIDIwMTgpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjEyPC9yZWMt

bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iZmZlc3pldzJwNWYwZjhl

MGRmNXB0NWR3cGY5ZjkyczB2YWR3IiB0aW1lc3RhbXA9IjE1MTc3OTU3ODQiPjEyPC9rZXk+PC9m

b3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBl

Pjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYXVkZSwgUy4gTC48L2F1dGhvcj48YXV0

aG9yPkxhZXRzY2gsIFQuIFcuPC9hdXRob3I+PGF1dGhvcj5CdWVjaG5lciwgSi48L2F1dGhvcj48

YXV0aG9yPlJpdmVzLCBTLjwvYXV0aG9yPjxhdXRob3I+Qm95ZXIsIE0uPC9hdXRob3I+PGF1dGhv

cj5CaXR0ZW5jb3VydCwgSC48L2F1dGhvcj48YXV0aG9yPkJhZGVyLCBQLjwvYXV0aG9yPjxhdXRo

b3I+VmVybmVyaXMsIE0uIFIuPC9hdXRob3I+PGF1dGhvcj5TdGVmYW5za2ksIEguIEUuPC9hdXRo

b3I+PGF1dGhvcj5NeWVycywgRy4gRC48L2F1dGhvcj48YXV0aG9yPlFheWVkLCBNLjwvYXV0aG9y

PjxhdXRob3I+RGUgTW9lcmxvb3NlLCBCLjwvYXV0aG9yPjxhdXRob3I+SGlyYW1hdHN1LCBILjwv

YXV0aG9yPjxhdXRob3I+U2NobGlzLCBLLjwvYXV0aG9yPjxhdXRob3I+RGF2aXMsIEsuIEwuPC9h

dXRob3I+PGF1dGhvcj5NYXJ0aW4sIFAuIEwuPC9hdXRob3I+PGF1dGhvcj5OZW1lY2VrLCBFLiBS

LjwvYXV0aG9yPjxhdXRob3I+WWFuaWssIEcuIEEuPC9hdXRob3I+PGF1dGhvcj5QZXRlcnMsIEMu

PC9hdXRob3I+PGF1dGhvcj5CYXJ1Y2hlbCwgQS48L2F1dGhvcj48YXV0aG9yPkJvaXNzZWwsIE4u

PC9hdXRob3I+PGF1dGhvcj5NZWNoaW5hdWQsIEYuPC9hdXRob3I+PGF1dGhvcj5CYWxkdXp6aSwg

QS48L2F1dGhvcj48YXV0aG9yPktydWVnZXIsIEouPC9hdXRob3I+PGF1dGhvcj5KdW5lLCBDLiBI

LjwvYXV0aG9yPjxhdXRob3I+TGV2aW5lLCBCLiBMLjwvYXV0aG9yPjxhdXRob3I+V29vZCwgUC48

L2F1dGhvcj48YXV0aG9yPlRhcmFuLCBULjwvYXV0aG9yPjxhdXRob3I+TGV1bmcsIE0uPC9hdXRo

b3I+PGF1dGhvcj5NdWVsbGVyLCBLLiBULjwvYXV0aG9yPjxhdXRob3I+WmhhbmcsIFkuPC9hdXRo

b3I+PGF1dGhvcj5TZW4sIEsuPC9hdXRob3I+PGF1dGhvcj5MZWJ3b2hsLCBELjwvYXV0aG9yPjxh

dXRob3I+UHVsc2lwaGVyLCBNLiBBLjwvYXV0aG9yPjxhdXRob3I+R3J1cHAsIFMuIEEuPC9hdXRo

b3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RnJvbSB0aGUgRGVwYXJ0

bWVudHMgb2YgUGVkaWF0cmljcyAoUy5MLk0uLCBTLkEuRy4pIGFuZCBQYXRob2xvZ3kgYW5kIExh

Ym9yYXRvcnkgTWVkaWNpbmUgKEMuSC5KLiwgQi5MLkwuKSwgUGVyZWxtYW4gU2Nob29sIG9mIE1l

ZGljaW5lLCBhbmQgQWJyYW1zb24gQ2FuY2VyIENlbnRlciAoQy5ILkouLCBCLkwuTC4pLCBVbml2

ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSwgYW5kIHRoZSBEaXZpc2lvbiBvZiBPbmNvbG9neSwgQ2Vu

dGVyIGZvciBDaGlsZGhvb2QgQ2FuY2VyIFJlc2VhcmNoIGFuZCBDYW5jZXIgSW1tdW5vdGhlcmFw

eSBQcm9ncmFtLCBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWwgb2YgUGhpbGFkZWxwaGlhIChTLkwu

TS4sIFMuQS5HLikgLSBhbGwgaW4gUGhpbGFkZWxwaGlhOyB0aGUgRGVwYXJ0bWVudCBvZiBQZWRp

YXRyaWNzIGFuZCBIYXJvbGQgQy4gU2ltbW9ucyBDb21wcmVoZW5zaXZlIENhbmNlciBDZW50ZXIs

IFVuaXZlcnNpdHkgb2YgVGV4YXMgU291dGh3ZXN0ZXJuIE1lZGljYWwgQ2VudGVyLCBhbmQgdGhl

IFBhdWxpbmUgQWxsZW4gR2lsbCBDZW50ZXIgZm9yIENhbmNlciBhbmQgQmxvb2QgRGlzb3JkZXJz

LCBDaGlsZHJlbiZhcG9zO3MgSGVhbHRoLCBEYWxsYXMgKFQuVy5MLik7IHRoZSBEZXBhcnRtZW50

IG9mIFBlZGlhdHJpYyBIZW1hdG9sb2d5IGFuZCBPbmNvbG9neSwgT3NsbyBVbml2ZXJzaXR5IEhv

c3BpdGFsLCBPc2xvIChKLkIuKTsgdGhlIERlcGFydG1lbnQgb2YgUGVkaWF0cmljIEhlbWF0b2xv

Z3kgYW5kIE9uY29sb2d5LCBIb3NwaXRhbCBTYW50IEpvYW4gZGUgRGV1IEJhcmNlbG9uYSwgQmFy

Y2Vsb25hIChTLlIuKTsgdGhlIERlcGFydG1lbnQgb2YgUGVkaWF0cmljcyBhbmQgSW50ZXJuYWwg

TWVkaWNpbmUsIFVuaXZlcnNpdHkgb2YgVXRhaCwgU2FsdCBMYWtlIENpdHkgKE0uQi4pOyB0aGUg

RGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBGYWN1bHR5IG9mIE1lZGljaW5lLCBVbml2ZXJzaXR5

IG9mIE1vbnRyZWFsLCBhbmQgdGhlIEhlbWF0b2xvZ3kgT25jb2xvZ3kgRGl2aXNpb24gYW5kIENo

YXJsZXMtQnJ1bmVhdSBDYW5jZXIgQ2VudGVyLCBDZW50cmUgSG9zcGl0YWxpZXIgVW5pdmVyc2l0

YWlyZSBTYWludGUtSnVzdGluZSBSZXNlYXJjaCBDZW50ZXIsIE1vbnRyZWFsIChILkIuKSwgYW5k

IHRoZSBEaXZpc2lvbiBvZiBIYWVtYXRvbG9neS9PbmNvbG9neS9Cb25lIE1hcnJvdyBUcmFuc3Bs

YW50YXRpb24sIEhvc3BpdGFsIGZvciBTaWNrIENoaWxkcmVuLCBUb3JvbnRvIChKLksuKSAtIGFs

bCBpbiBDYW5hZGE7IHRoZSBEaXZpc2lvbiBvZiBTdGVtIENlbGwgVHJhbnNwbGFudGF0aW9uIGFu

ZCBJbW11bm9sb2d5LCBIb3NwaXRhbCBmb3IgQ2hpbGRyZW4gYW5kIEFkb2xlc2NlbnRzLCBVbml2

ZXJzaXR5IEhvc3BpdGFsIEZyYW5rZnVydCwgRnJhbmtmdXJ0LCBHZXJtYW55IChQLkIuKTsgdGhl

IERpdmlzaW9uIG9mIFBlZGlhdHJpYyBCbG9vZCBhbmQgTWFycm93IFRyYW5zcGxhbnQsIFVuaXZl

cnNpdHkgb2YgTWlubmVzb3RhLCBNaW5uZWFwb2xpcyAoTS5SLlYuLCBILkUuUy4pOyBDaGlsZHJl

biZhcG9zO3MgTWVyY3kgSG9zcGl0YWwgYW5kIENsaW5pY3MsIEthbnNhcyBDaXR5LCBNTyAoRy5E

Lk0uKTsgQWZsYWMgQ2FuY2VyIGFuZCBCbG9vZCBEaXNvcmRlcnMgQ2VudGVyLCBFbW9yeSBVbml2

ZXJzaXR5LCBBdGxhbnRhIChNLlEuKTsgdGhlIERlcGFydG1lbnQgb2YgUGVkaWF0cmljIEhlbWF0

b2xvZ3ktT25jb2xvZ3kgYW5kIFN0ZW0gQ2VsbCBUcmFuc3BsYW50YXRpb24sIEdoZW50IFVuaXZl

cnNpdHkgSG9zcGl0YWwsIGFuZCB0aGUgQ2FuY2VyIFJlc2VhcmNoIEluc3RpdHV0ZSBHaGVudCAo

Q1JJRyksIEdoZW50LCBCZWxnaXVtIChCLkQuTS4pOyB0aGUgRGVwYXJ0bWVudCBvZiBQZWRpYXRy

aWNzLCBHcmFkdWF0ZSBTY2hvb2wgb2YgTWVkaWNpbmUgS3lvdG8gVW5pdmVyc2l0eSwgS3lvdG8s

IEphcGFuIChILkguKTsgdGhlIERlcGFydG1lbnQgb2YgUGVkaWF0cmljcywgU3RhbmZvcmQgVW5p

dmVyc2l0eSBTY2hvb2wgb2YgTWVkaWNpbmUsIFN0YW5mb3JkIChLLiBTY2hsaXMsIEsuTC5ELiks

IGFuZCB0aGUgRGl2aXNpb24gb2YgSGVtYXRvbG9neSwgT25jb2xvZ3ksIEJsb29kIGFuZCBNYXJy

b3cgVHJhbnNwbGFudCwgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsIExvcyBBbmdlbGVzLCBVU0Mg

S2VjayBTY2hvb2wgb2YgTWVkaWNpbmUsIExvcyBBbmdlbGVzIChNLkEuUC4pIC0gYWxsIGluIENh

bGlmb3JuaWE7IHRoZSBEaXZpc2lvbiBvZiBQZWRpYXRyaWMgQmxvb2QgYW5kIE1hcnJvdyBUcmFu

c3BsYW50LCBEdWtlIFVuaXZlcnNpdHkgTWVkaWNhbCBDZW50ZXIsIER1cmhhbSwgTkMgKFAuTC5N

Lik7IE9yZWdvbiBIZWFsdGggYW5kIFNjaWVuY2UgVW5pdmVyc2l0eSwgUG9ydGxhbmQgKEUuUi5O

Lik7IEMuUy4gTW90dCBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWwsIEFubiBBcmJvciwgTUkgKEcu

QS5ZLik7IHRoZSBTdGVtIENlbGwgVHJhbnNwbGFudGF0aW9uIFVuaXQsIFN0LiBBbm5hIENoaWxk

cmVuJmFwb3M7cyBIb3NwaXRhbCwgVmllbm5hIChDLlAuKTsgVW5pdmVyc2l0eSBIb3NwaXRhbCBS

b2JlcnQgRGVicmUgYW5kIFVuaXZlcnNpdHkgUGFyaXMgRGlkZXJvdCAoQS4gQmFydWNoZWwpLCBh

bmQgU2FpbnQtTG91aXMgSG9zcGl0YWwgYW5kIFVuaXZlcnNpdHkgUGFyaXMgRGlkZXJvdCAoTi5C

LiksIFBhcmlzOyB0aGUgUm95YWwgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsLCBNZWxib3VybmUs

IFZJQywgQXVzdHJhbGlhIChGLk0uKTsgQ2xpbmljYSBQZWRpYXRyaWNhIFVuaXZlcnNpdGEgZGVn

bGkgU3R1ZGkgZGkgTWlsYW5vIEJpY29jY2EsIE1vbnphLCBJdGFseSAoQS4gQmFsZHV6emkpOyBh

bmQgTm92YXJ0aXMgUGhhcm1hY2V1dGljYWxzIChQLlcuLCBULlQuLCBNLkwuLCBZLlouLCBLLiBT

ZW4sIEQuTC4pIGFuZCBOb3ZhcnRpcyBJbnN0aXR1dGVzIGZvciBCaW9tZWRpY2FsIFJlc2VhcmNo

IChLLlQuTS4pIC0gYm90aCBpbiBFYXN0IEhhbm92ZXIsIE5KLjwvYXV0aC1hZGRyZXNzPjx0aXRs

ZXM+PHRpdGxlPlRpc2FnZW5sZWNsZXVjZWwgaW4gQ2hpbGRyZW4gYW5kIFlvdW5nIEFkdWx0cyB3

aXRoIEItQ2VsbCBMeW1waG9ibGFzdGljIExldWtlbWlhPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl

Pk4gRW5nbCBKIE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxs

LXRpdGxlPk4gRW5nbCBKIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjQzOS00

NDg8L3BhZ2VzPjx2b2x1bWU+Mzc4PC92b2x1bWU+PG51bWJlcj41PC9udW1iZXI+PGRhdGVzPjx5

ZWFyPjIwMTg8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5GZWIgMTwvZGF0ZT48L3B1Yi1kYXRlcz48

L2RhdGVzPjxpc2JuPjE1MzMtNDQwNiAoRWxlY3Ryb25pYykmI3hEOzAwMjgtNDc5MyAoTGlua2lu

Zyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjkzODUzNzA8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJl

bGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjkzODUz

NzA8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEw

LjEwNTYvTkVKTW9hMTcwOTg2NjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9D

aXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYXVkZTwvQXV0aG9yPjxZZWFyPjIwMTg8L1llYXI+PFJl

Y051bT4xMjwvUmVjTnVtPjxJRFRleHQ+NDM5LTQ0ODwvSURUZXh0PjxEaXNwbGF5VGV4dD4oTWF1

ZGUgZXQgYWwuIDIwMTgpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjEyPC9yZWMt

bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iZmZlc3pldzJwNWYwZjhl

MGRmNXB0NWR3cGY5ZjkyczB2YWR3IiB0aW1lc3RhbXA9IjE1MTc3OTU3ODQiPjEyPC9rZXk+PC9m

b3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBl

Pjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYXVkZSwgUy4gTC48L2F1dGhvcj48YXV0

aG9yPkxhZXRzY2gsIFQuIFcuPC9hdXRob3I+PGF1dGhvcj5CdWVjaG5lciwgSi48L2F1dGhvcj48

YXV0aG9yPlJpdmVzLCBTLjwvYXV0aG9yPjxhdXRob3I+Qm95ZXIsIE0uPC9hdXRob3I+PGF1dGhv

cj5CaXR0ZW5jb3VydCwgSC48L2F1dGhvcj48YXV0aG9yPkJhZGVyLCBQLjwvYXV0aG9yPjxhdXRo

b3I+VmVybmVyaXMsIE0uIFIuPC9hdXRob3I+PGF1dGhvcj5TdGVmYW5za2ksIEguIEUuPC9hdXRo

b3I+PGF1dGhvcj5NeWVycywgRy4gRC48L2F1dGhvcj48YXV0aG9yPlFheWVkLCBNLjwvYXV0aG9y

PjxhdXRob3I+RGUgTW9lcmxvb3NlLCBCLjwvYXV0aG9yPjxhdXRob3I+SGlyYW1hdHN1LCBILjwv

YXV0aG9yPjxhdXRob3I+U2NobGlzLCBLLjwvYXV0aG9yPjxhdXRob3I+RGF2aXMsIEsuIEwuPC9h

dXRob3I+PGF1dGhvcj5NYXJ0aW4sIFAuIEwuPC9hdXRob3I+PGF1dGhvcj5OZW1lY2VrLCBFLiBS

LjwvYXV0aG9yPjxhdXRob3I+WWFuaWssIEcuIEEuPC9hdXRob3I+PGF1dGhvcj5QZXRlcnMsIEMu

PC9hdXRob3I+PGF1dGhvcj5CYXJ1Y2hlbCwgQS48L2F1dGhvcj48YXV0aG9yPkJvaXNzZWwsIE4u

PC9hdXRob3I+PGF1dGhvcj5NZWNoaW5hdWQsIEYuPC9hdXRob3I+PGF1dGhvcj5CYWxkdXp6aSwg

QS48L2F1dGhvcj48YXV0aG9yPktydWVnZXIsIEouPC9hdXRob3I+PGF1dGhvcj5KdW5lLCBDLiBI

LjwvYXV0aG9yPjxhdXRob3I+TGV2aW5lLCBCLiBMLjwvYXV0aG9yPjxhdXRob3I+V29vZCwgUC48

L2F1dGhvcj48YXV0aG9yPlRhcmFuLCBULjwvYXV0aG9yPjxhdXRob3I+TGV1bmcsIE0uPC9hdXRo

b3I+PGF1dGhvcj5NdWVsbGVyLCBLLiBULjwvYXV0aG9yPjxhdXRob3I+WmhhbmcsIFkuPC9hdXRo

b3I+PGF1dGhvcj5TZW4sIEsuPC9hdXRob3I+PGF1dGhvcj5MZWJ3b2hsLCBELjwvYXV0aG9yPjxh

dXRob3I+UHVsc2lwaGVyLCBNLiBBLjwvYXV0aG9yPjxhdXRob3I+R3J1cHAsIFMuIEEuPC9hdXRo

b3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RnJvbSB0aGUgRGVwYXJ0

bWVudHMgb2YgUGVkaWF0cmljcyAoUy5MLk0uLCBTLkEuRy4pIGFuZCBQYXRob2xvZ3kgYW5kIExh

Ym9yYXRvcnkgTWVkaWNpbmUgKEMuSC5KLiwgQi5MLkwuKSwgUGVyZWxtYW4gU2Nob29sIG9mIE1l

ZGljaW5lLCBhbmQgQWJyYW1zb24gQ2FuY2VyIENlbnRlciAoQy5ILkouLCBCLkwuTC4pLCBVbml2

ZXJzaXR5IG9mIFBlbm5zeWx2YW5pYSwgYW5kIHRoZSBEaXZpc2lvbiBvZiBPbmNvbG9neSwgQ2Vu

dGVyIGZvciBDaGlsZGhvb2QgQ2FuY2VyIFJlc2VhcmNoIGFuZCBDYW5jZXIgSW1tdW5vdGhlcmFw

eSBQcm9ncmFtLCBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWwgb2YgUGhpbGFkZWxwaGlhIChTLkwu

TS4sIFMuQS5HLikgLSBhbGwgaW4gUGhpbGFkZWxwaGlhOyB0aGUgRGVwYXJ0bWVudCBvZiBQZWRp

YXRyaWNzIGFuZCBIYXJvbGQgQy4gU2ltbW9ucyBDb21wcmVoZW5zaXZlIENhbmNlciBDZW50ZXIs

IFVuaXZlcnNpdHkgb2YgVGV4YXMgU291dGh3ZXN0ZXJuIE1lZGljYWwgQ2VudGVyLCBhbmQgdGhl

IFBhdWxpbmUgQWxsZW4gR2lsbCBDZW50ZXIgZm9yIENhbmNlciBhbmQgQmxvb2QgRGlzb3JkZXJz

LCBDaGlsZHJlbiZhcG9zO3MgSGVhbHRoLCBEYWxsYXMgKFQuVy5MLik7IHRoZSBEZXBhcnRtZW50

IG9mIFBlZGlhdHJpYyBIZW1hdG9sb2d5IGFuZCBPbmNvbG9neSwgT3NsbyBVbml2ZXJzaXR5IEhv

c3BpdGFsLCBPc2xvIChKLkIuKTsgdGhlIERlcGFydG1lbnQgb2YgUGVkaWF0cmljIEhlbWF0b2xv

Z3kgYW5kIE9uY29sb2d5LCBIb3NwaXRhbCBTYW50IEpvYW4gZGUgRGV1IEJhcmNlbG9uYSwgQmFy

Y2Vsb25hIChTLlIuKTsgdGhlIERlcGFydG1lbnQgb2YgUGVkaWF0cmljcyBhbmQgSW50ZXJuYWwg

TWVkaWNpbmUsIFVuaXZlcnNpdHkgb2YgVXRhaCwgU2FsdCBMYWtlIENpdHkgKE0uQi4pOyB0aGUg

RGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBGYWN1bHR5IG9mIE1lZGljaW5lLCBVbml2ZXJzaXR5

IG9mIE1vbnRyZWFsLCBhbmQgdGhlIEhlbWF0b2xvZ3kgT25jb2xvZ3kgRGl2aXNpb24gYW5kIENo

YXJsZXMtQnJ1bmVhdSBDYW5jZXIgQ2VudGVyLCBDZW50cmUgSG9zcGl0YWxpZXIgVW5pdmVyc2l0

YWlyZSBTYWludGUtSnVzdGluZSBSZXNlYXJjaCBDZW50ZXIsIE1vbnRyZWFsIChILkIuKSwgYW5k

IHRoZSBEaXZpc2lvbiBvZiBIYWVtYXRvbG9neS9PbmNvbG9neS9Cb25lIE1hcnJvdyBUcmFuc3Bs

YW50YXRpb24sIEhvc3BpdGFsIGZvciBTaWNrIENoaWxkcmVuLCBUb3JvbnRvIChKLksuKSAtIGFs

bCBpbiBDYW5hZGE7IHRoZSBEaXZpc2lvbiBvZiBTdGVtIENlbGwgVHJhbnNwbGFudGF0aW9uIGFu

ZCBJbW11bm9sb2d5LCBIb3NwaXRhbCBmb3IgQ2hpbGRyZW4gYW5kIEFkb2xlc2NlbnRzLCBVbml2

ZXJzaXR5IEhvc3BpdGFsIEZyYW5rZnVydCwgRnJhbmtmdXJ0LCBHZXJtYW55IChQLkIuKTsgdGhl

IERpdmlzaW9uIG9mIFBlZGlhdHJpYyBCbG9vZCBhbmQgTWFycm93IFRyYW5zcGxhbnQsIFVuaXZl

cnNpdHkgb2YgTWlubmVzb3RhLCBNaW5uZWFwb2xpcyAoTS5SLlYuLCBILkUuUy4pOyBDaGlsZHJl

biZhcG9zO3MgTWVyY3kgSG9zcGl0YWwgYW5kIENsaW5pY3MsIEthbnNhcyBDaXR5LCBNTyAoRy5E

Lk0uKTsgQWZsYWMgQ2FuY2VyIGFuZCBCbG9vZCBEaXNvcmRlcnMgQ2VudGVyLCBFbW9yeSBVbml2

ZXJzaXR5LCBBdGxhbnRhIChNLlEuKTsgdGhlIERlcGFydG1lbnQgb2YgUGVkaWF0cmljIEhlbWF0

b2xvZ3ktT25jb2xvZ3kgYW5kIFN0ZW0gQ2VsbCBUcmFuc3BsYW50YXRpb24sIEdoZW50IFVuaXZl

cnNpdHkgSG9zcGl0YWwsIGFuZCB0aGUgQ2FuY2VyIFJlc2VhcmNoIEluc3RpdHV0ZSBHaGVudCAo

Q1JJRyksIEdoZW50LCBCZWxnaXVtIChCLkQuTS4pOyB0aGUgRGVwYXJ0bWVudCBvZiBQZWRpYXRy

aWNzLCBHcmFkdWF0ZSBTY2hvb2wgb2YgTWVkaWNpbmUgS3lvdG8gVW5pdmVyc2l0eSwgS3lvdG8s

IEphcGFuIChILkguKTsgdGhlIERlcGFydG1lbnQgb2YgUGVkaWF0cmljcywgU3RhbmZvcmQgVW5p

dmVyc2l0eSBTY2hvb2wgb2YgTWVkaWNpbmUsIFN0YW5mb3JkIChLLiBTY2hsaXMsIEsuTC5ELiks

IGFuZCB0aGUgRGl2aXNpb24gb2YgSGVtYXRvbG9neSwgT25jb2xvZ3ksIEJsb29kIGFuZCBNYXJy

b3cgVHJhbnNwbGFudCwgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsIExvcyBBbmdlbGVzLCBVU0Mg

S2VjayBTY2hvb2wgb2YgTWVkaWNpbmUsIExvcyBBbmdlbGVzIChNLkEuUC4pIC0gYWxsIGluIENh

bGlmb3JuaWE7IHRoZSBEaXZpc2lvbiBvZiBQZWRpYXRyaWMgQmxvb2QgYW5kIE1hcnJvdyBUcmFu

c3BsYW50LCBEdWtlIFVuaXZlcnNpdHkgTWVkaWNhbCBDZW50ZXIsIER1cmhhbSwgTkMgKFAuTC5N

Lik7IE9yZWdvbiBIZWFsdGggYW5kIFNjaWVuY2UgVW5pdmVyc2l0eSwgUG9ydGxhbmQgKEUuUi5O

Lik7IEMuUy4gTW90dCBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWwsIEFubiBBcmJvciwgTUkgKEcu

QS5ZLik7IHRoZSBTdGVtIENlbGwgVHJhbnNwbGFudGF0aW9uIFVuaXQsIFN0LiBBbm5hIENoaWxk

cmVuJmFwb3M7cyBIb3NwaXRhbCwgVmllbm5hIChDLlAuKTsgVW5pdmVyc2l0eSBIb3NwaXRhbCBS

b2JlcnQgRGVicmUgYW5kIFVuaXZlcnNpdHkgUGFyaXMgRGlkZXJvdCAoQS4gQmFydWNoZWwpLCBh

bmQgU2FpbnQtTG91aXMgSG9zcGl0YWwgYW5kIFVuaXZlcnNpdHkgUGFyaXMgRGlkZXJvdCAoTi5C

LiksIFBhcmlzOyB0aGUgUm95YWwgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsLCBNZWxib3VybmUs

IFZJQywgQXVzdHJhbGlhIChGLk0uKTsgQ2xpbmljYSBQZWRpYXRyaWNhIFVuaXZlcnNpdGEgZGVn

bGkgU3R1ZGkgZGkgTWlsYW5vIEJpY29jY2EsIE1vbnphLCBJdGFseSAoQS4gQmFsZHV6emkpOyBh

bmQgTm92YXJ0aXMgUGhhcm1hY2V1dGljYWxzIChQLlcuLCBULlQuLCBNLkwuLCBZLlouLCBLLiBT

ZW4sIEQuTC4pIGFuZCBOb3ZhcnRpcyBJbnN0aXR1dGVzIGZvciBCaW9tZWRpY2FsIFJlc2VhcmNo

IChLLlQuTS4pIC0gYm90aCBpbiBFYXN0IEhhbm92ZXIsIE5KLjwvYXV0aC1hZGRyZXNzPjx0aXRs

ZXM+PHRpdGxlPlRpc2FnZW5sZWNsZXVjZWwgaW4gQ2hpbGRyZW4gYW5kIFlvdW5nIEFkdWx0cyB3

aXRoIEItQ2VsbCBMeW1waG9ibGFzdGljIExldWtlbWlhPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl

Pk4gRW5nbCBKIE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxs

LXRpdGxlPk4gRW5nbCBKIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjQzOS00

NDg8L3BhZ2VzPjx2b2x1bWU+Mzc4PC92b2x1bWU+PG51bWJlcj41PC9udW1iZXI+PGRhdGVzPjx5

ZWFyPjIwMTg8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5GZWIgMTwvZGF0ZT48L3B1Yi1kYXRlcz48

L2RhdGVzPjxpc2JuPjE1MzMtNDQwNiAoRWxlY3Ryb25pYykmI3hEOzAwMjgtNDc5MyAoTGlua2lu

Zyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjkzODUzNzA8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJl

bGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjkzODUz

NzA8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEw

LjEwNTYvTkVKTW9hMTcwOTg2NjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9D

aXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA (Maude et al. 2018). For 3 to 4 weeks after infusion of tisagenlecleucel, it is recommended that patients stay within 2?hours of the hospital where they received the treatment, for monitoring purposes. REDACTED. Interventions which may be required during the post-treatment monitoring period include oxygen, fluids, vasopressor support and antipyretics. After the first month, the clinical trials reported/recommended standard follow-up visits every month for the first 6 months post-treatment, followed by 3-monthly for the rest of the year and 6-monthly thereafter. Patients should be monitored long-term for potential late onset toxicities, and considered for immunoglobulin therapy in the event of B-cell depletion or hypogammaglobinemia.REDACTED.Funding mechanism and current funding of pharmaceutical componentsTisagenlecleucel (brand name Kymriah?) has been classified as a class 4 biological product. It is therefore not eligible to be funded through the Pharmaceutical Benefits Scheme (PBS). REDACTED Tisagenlecleucel is currently provided for certain patients under the Medical Treatment Overseas Program, costing upwards of A$1million per patient.The remaining components of the process (numbers 1, 5 and 6 in REF _Ref503438152 \h \* MERGEFORMAT Figure 2) would be performed within the Australian REDACTED hospital setting. Patients would receive lymphodepleting chemotherapy, which is currently covered by the PBS, prior to receiving tisagenlecleucel. This includes fludarabine, cyclophosphamide, cytarabine, etoposide, and bendamustine (listed as Section 100 Chemotherapy items for Public Hospital Use). For pharmaceuticals likely to be used during CAR-T therapy (which are already listed on the PBS or through the National Blood Authority), see REF _Ref504035517 \h \* MERGEFORMAT Table 3. Siltuximab would be used for the treatment of CRS where tocilizumab is not suitable. If both tocilizumab and siltuximab are ineffective, anti-T cell therapies such as cyclophosphamide, anti-thymocyte globulin or alemtuzumab should also be considered. In patients with low immunoglobulin levels pre-emptive measures such as immunoglobulin replacement should be implemented as per age and standard guidelines.Table SEQ Table \* ARABIC 3 Pharmaceuticals associated with the CAR-T therapy process PharmaceuticalUsagePBS item code / fundingFludarabineChemotherapy for public hospital use, antimetabolite4393FCyclophosphamideChemotherapy for public hospital use, alkylating agent4327RCytarabineChemotherapy for public hospital use, antimetabolite4357HEtoposideChemotherapy for public hospital use, plant alkaloids and other natural products4428CBendamustineChemotherapy for public hospital use, alkylating agent (for previously untreated stage II or IV indolent CD20 positive non-Hodgkin lymphoma)10760HTocilizumabTreatment of CRS Funding costs based on PBS codes:1056G, 1058J, 10060L, 10064Q, 10068X, 10071C, 10072D, 10073E, 10077J, 10078K, 10079L, 10081NIntravenous immunoglobulinTo manage events of B-cell aplasia (Funded through National Blood Authority for different indications)SiltuximabTreatment of CRS, in cases where tocilizumab is not suitableATC code: L04AC11AlemtuzumabTreatment of CRS, in cases where tocilizumab or siltuximab is not suitableFunding costs based on PBS codes:10228H, 10232M, 10243D, 10246GATC = Anatomical Therapeutic Chemical, CRS = cytokine release syndromeThe leukapheresis requires a specialised apheresis unit, with tubing moving blood through centrifuges and/or filters to separate the different blood products. Single use consumables used during leukapheresis include sets, tubing, bowls, anticoagulant and replacement fluids. It is unclear if leukapheresis (to retrieve the leukocytes needed to manufacture tisagenlecleucel) is currently covered under the MBS. A broader item (13750), therapeutic haemapheresis, is currently listed for the removal of plasma or cellular (or both) elements of blood, utilising continuous or intermittent flow techniques. This includes morphological tests for cell counts and viability studies, if performed. During the procedure there is continuous monitoring of vital signs, fluid balance, blood volume and other parameters with registered nurse attendance under the supervision of a consultant physician. The fee for this service is $136.65. REDACTED.The Department of Health should consider which components of the process should be covered under the proposed intervention, and which remaining parts of the process will continue to be funded by the current funding mechanisms/bodies. REDACTED.Estimated uptake of the interventionThe applicant estimated an incidence of 210 patients with paediatric ALL with B-cell lineage, of which an estimated 28 patients would be eligible for the intervention each year (under the proposed criteria). The estimated incidence and eligibility is 2,070 and 720 for the DLBCL population, respectively. These estimates were proposed when tisagenlecleucel was considered to be only a last- line therapy. The indications have since changed, and PASC considered that this change would likely increase the number of patients eligible for the intervention.However, not all the patients eligible for the intervention will receive the intervention, due to the relative frailty of the populations or due to the apheresis product not being acceptable for manufacturing. This is supported by the recent study by Maude et al., which reported that of the 107 ALL patients screened, 92 were enrolled, 75 underwent the infusion, and only 48 remained in the follow-up. In the study by Schuster et al., 13 out of 24 enrolled DLBCL patients received tisagenlecleucel infusion (61%). Most patients were excluded due to death, adverse events, and product-related issues, or discontinued the treatment/follow-up due to death, undergoing new therapies, or lack of efficacy of the treatment. REDACTED.2.3.1 RationaleSee 2.1.1. This technology will continue to be developed/improved. In the future, CAR-T immunotherapies and CRISPR/Cas9 might be combined to reduce the adverse effects of CAR-T therapy. CRISPR may improve the engineering of T cells and increase specificity, or deliver it to a very specific site. Therefore, it is expected that other CAR-T therapies will follow this same pathway in the coming years. This application is likely to be the first of a series of applications, and the mechanism under which it may be funded may become an example on how to regulate future (autologous) products of gene-editing. REDACTED.2.5 ComparatorThe applicant states that in most sub-populations in the ALL group, the appropriate comparator is best supportive care (BSC), consisting of further minimally toxic chemotherapy or palliative care (or an experimental treatment through a clinical trial). This is often the last line of therapy. The comparator for the DLBCL sub-groups is salvage chemotherapy, consisting of a mix of predominantly rituximab based chemotherapy regimens. For the comparators per sub-population, see REF _Ref514076294 \h Table 4. Table SEQ Table \* ARABIC 4 Proposed comparators, per population sub-groupALLSub-populationComparator2nd or greater bone marrow relapseBest supportive careBone marrow relapse following allogenic SCTSalvage chemotherapy with intention to proceed to allogenic SCT, clofarabine with intention to proceed to allogenic SCT, or in some cases BSC (or a clinical trial) (when refractory after TKI+ chemotherapy and allogenic SCT)Primary refractory, as defined by not achieving a complete response after two cycles of standard chemotherapySalvage chemotherapy with intention to proceed to allogenic SCT, or clofarabine with intention to proceed to allogenic SCTChemo refractory, as defined by not achieving complete response after one cycle of standard chemotherapy for relapsed ALLBest supportive carePhiladelphia chromosome positive and intolerant, contraindicated or failed two lines of TKI therapy Best supportive careIneligible for allogenic SCT due to comorbid disease, contraindications to the conditioning regimen, prior SCT, or lack of a suitable donorBest supportive careDLBCLSub-populationComparatorRelapsed/refractory disease after two lines of chemotherapy and relapse after autologous SCTSalvage chemotherapyRelapsed/refractory disease after two lines of chemotherapy and ineligible for subsequent stem cell transplantSalvage chemotherapyALL = acute lymphoblastic leukaemia, BSC = best supportive care DLBCL = diffuse large B-cell lymphoma, SCT = Stem Cell Transplant, TKI = thyrosine kinase inhibitorThe standard of BSC is ill-defined. The applicant reported that BSC most likely comprises a salvage regimen of fludarabine, cytarabine and/or idarubicin, or alternatively clofarabine. Supportive care in cancer should address the following domains: (1) the physical domain, including physical symptoms requiring continuing interventions or rehabilitation; (2) the psychological domain, which addresses issues related to the patient’s mental health and personal relationships; (3) the social domain, which includes social and practical issues impacting the individual and family (e.g. emotional support, maintaining social networks); (4) information domain, addressing access to information about cancer and support services; (5) spiritual domain, focusing on the patient’s changing sense of self and challenges to their beliefs and existential concerns ADDIN EN.CITE <EndNote><Cite><Author>National Cancer Expert Reference Group</Author><Year>2016</Year><RecNum>8</RecNum><DisplayText>(National Cancer Expert Reference Group 2016)</DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1516148325">8</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>National Cancer Expert Reference Group,.</author></authors></contributors><titles><title>Optimal cancer care pathway for people with Hodgkin and diffuse large B-cell lymphomas</title></titles><dates><year>2016</year></dates><publisher>Australian Government Cancer Australia and Cancer Council</publisher><urls></urls></record></Cite></EndNote>(National Cancer Expert Reference Group 2016). The Institute for Clinical and Economic Review reported clofarabine-based therapy and blinatumomab-based therapy as comparators in the ALL population, and salvage chemotherapy regimens in the lymphoma population ADDIN EN.CITE <EndNote><Cite><Author>Institute for Clinical and Economic Review (ICER)</Author><Year>2017</Year><RecNum>9</RecNum><DisplayText>(Institute for Clinical and Economic Review (ICER) 2017)</DisplayText><record><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1516335195">9</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Institute for Clinical and Economic Review (ICER),.</author></authors></contributors><titles><title>Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value, Draft evidence report</title></titles><dates><year>2017</year><pub-dates><date>December 19,2017</date></pub-dates></dates><publisher>Institute for Clinical and Economic Review,</publisher><urls></urls></record></Cite></EndNote>(Institute for Clinical and Economic Review (ICER) 2017). Clofarabine is currently listed as an orphan drug on the TGA for paediatric ALL patients who have relapsed or are refractory, however it is not PBS listed, has not been appraised by the PBAC, and the drug is expensive (up to $100,000 a year). ADDIN EN.CITE <EndNote><Cite><Author>Kirby</Author><Year>2014</Year><RecNum>14</RecNum><IDText>923</IDText><DisplayText>(Kirby 2014)</DisplayText><record><rec-number>14</rec-number><foreign-keys><key app="EN" db-id="ffeszew2p5f0f8e0df5pt5dwpf9f92s0vadw" timestamp="1520296612">14</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kirby, T.</author></authors></contributors><titles><title>Children&apos;s cancer drugs cut into Australian hospital budgets</title><secondary-title>Lancet Oncol</secondary-title></titles><periodical><full-title>Lancet Oncol</full-title></periodical><pages>923</pages><volume>15</volume><number>9</number><keywords><keyword>Antineoplastic Agents/*economics/therapeutic use</keyword><keyword>Australia</keyword><keyword>Budgets</keyword><keyword>Child</keyword><keyword>Child, Preschool</keyword><keyword>Drug Costs/*statistics &amp; numerical data</keyword><keyword>Female</keyword><keyword>*Hospital Costs</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Needs Assessment</keyword><keyword>Neoplasms/diagnosis/*drug therapy</keyword><keyword>Pediatrics</keyword></keywords><dates><year>2014</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>1474-5488 (Electronic)&#xD;1470-2045 (Linking)</isbn><accession-num>25225685</accession-num><urls><related-urls><url>;(Kirby 2014) It remains unclear how often clofarabine is used in paediatric ALL in Australia, or its average cost in a specialist public hospital setting. The proposed medical service is expected to supplement and substitute current clinical practice (e.g. BSC). Even though an experimental treatment through a clinical trial is not considered as a valid comparator to assess the safety and effectiveness of the intervention, it should be noted that it is expected a certain proportion of the patient population is likely to participate in clinical trials, which may impact the estimated population using the service. This will be relevant for the financial section of the assessment report. 2.4.1 RationaleComparative trials appear to be lacking. Most of the studies done on CAR-T therapies for B-Cell cancers are single-arm trials. 2.6 OutcomesThe overall clinical claim made by the applicant is for superiority. REDACTED.2.5.1 Patient relevantClinical effectiveness:Overall response rate (ORR), complete response rate, relapse-free survival, overall survival (OS), event-free survival, quality of life (QoL), health related quality of life (HRQoL), rate of complete remission, rate of partial remission, duration of response, time to return to daily activities Clinical efficacy:Tisagenlecleucel failure rate, percentage of patients successfully receiving tisagenlecleucel after starting the process, time from leukapheresis to receiving tisagenlecleucelSafety:Rate of adverse events (AEs) and serious adverse events (SAEs), events of special interest (e.g. cytokine release syndrome, tumour lysis syndrome, febrile neutropenia), AEs due to medications, neurotoxicity, infections, secondary cancers. Both the safety and effectiveness should be assessed including patients undergoing cell collection (not only patients receiving tisagenlecleucel). Patients who undergo cell collection are exposed to harms, and it should be noted that not everyone who undergoes cell collection will end up receiving tisagenlecleucel. This is most likely due to the time needed to prepare for the intervention. In addition, patients eligible for the intervention are already very sick and while waiting for administration of tisagenlecleucel may have disease progression, chemotherapy side effects, comorbidities, or the patient may have died. Therefore it is important that the trials included in the evidence include the ‘intent to treat’ population). If pre-treatments are required before leukapheresis, the whole ‘pre-treatment’ population should be included in the assessment. 2.5.2 Healthcare systemCost-effectiveness:Cost (including of additional pre-infusion and post-infusion interventions), cost per life year gained (LYG), cost per quality adjusted life year (QALY) or disability adjusted life year (DALY), incremental cost-effectiveness ratioFinancial implications:Number of patients suitable for treatment, number of patients who receive treatment PASC recommend that the overall incremental healthcare system costs be identified for the cost-effectiveness assessment, with these to be disaggregated to potentially different funders in the financial implications assessment.PASC recommended that the costs will need to be considered carefully, including:Cost of adverse events, especially cytokine release syndrome in the short-term and its management (PASC noted that some of the proposed management options may involve prolonged admission to an intensive care unit, and some others, including tocilizumab and siltuximab in particular, are not PBS-subsidised and have not been appraised by PBAC for this purpose).Cost of ongoing post-infusion therapy with intravenous immunoglobulin (IVIg), and cost of any subsequent stem cell transplants to consolidate a response to tisagenlecleucel (however, PASC acknowledged that horizon scanning of these longer-term costs would be difficult because of the current short-term follow-up within the specific study populations, so suggested that, conservatively, IVIg should be assumed to be lifelong)Cost of healthcare resources aligned across the three hospital sites in Australia.2.5.3 Other secondary outcomesUse of ‘rescue medication’ or similar while undergoing tisagenlecleucel therapy, versus use during best supportive care (e.g. filgrastim, epoetin, corticosteroids, etc)Rate of hospitalisations, healthcare resource utilisation, length of hospital stay and ICU admissions during and after CAR-T therapy, compared with the comparators.3. Current and proposed clinical management algorithm for identified populationThe applicant provided clinical management algorithms explaining the pathways the different patient populations will follow before he or she is eligible for the intervention (or the comparator). The solid lines represent the current pathways, the dotted lines the proposed changes with the addition of tisagenlecleucel (the proposed pathway). The light grey lines represent the largely theoretical patients who would technically be eligible for the intervention, but would be very scarce in clinical practice. The circles indicate the proposed sub-populations (numbered sub-populations are explained in section 2.2), and the diamonds show the most likely comparators for the specific sub-populations. Treatment options following the intervention are also shown, noting that patients would not be eligible for a second tisagenlecleucel infusion. PASC noted the current uncertainty relates to whether, in future, there would be pressure to provide one or more subsequent infusions of tisagenlecleucel, and advised that the submission-based assessment and MSAC consider (prospectively) how this risk might best be managed.The clinical management algorithms presented in the REF _Ref505600920 \h \* MERGEFORMAT Appendix aim to explain the current and proposed approaches to management of any downstream services and outcomes for the proposed populations, once they are identified. This means the starting points for the current management algorithm are the target populations. The blue pathways represent the proposed intervention, with the black pathways representing the current management. The dotted lines indicate that patients can drop out at different steps of the treatment process.-2628905847715Figure SEQ Figure \* ARABIC 3 Current and proposed clinical management algorithm for population 1 (ALL)Figure SEQ Figure \* ARABIC 3 Current and proposed clinical management algorithm for population 1 (ALL)Figure SEQ Figure \* ARABIC 4 Current and proposed clinical management algorithm for population 2 (DLBCL)4. Proposed economic evaluationThe applicant proposes that tisagenlecleucel is superior to the comparators in both populations (ALL and DLBCL).If this claim is supported by the clinical evidence, which will be presented in the clinical section of the assessment, a cost-utility analysis would be the most appropriate type of economic evaluation. 5. Proposed item descriptorAs specified in section 2.4 ‘Intervention’ (under Funding mechanism and coverage of pharmaceutical components), no public funding through the MBS is sought for tisagenlecleucel. There will therefore be no MBS item descriptor. FeeREDACTED. A fixed fee should be provided in the assessment report as it is necessary for ESC, and should be a fixed cost in Australian dollars (US dollar will be susceptible to exchange rates), or a fixed range of costs for the purposes of the cost-effectiveness analysis.REDACTED.6. References ADDIN EN.REFLIST Australian Institute of Health and Welfare (AIHW) 2017, Australian Cancer Incidence and Mortality (ACIM) books: Acute lymphoblastic leukaemia (ALL), Australian Institute of Health and Welfare (AIHW), Canberra.Brudno, JN & Kochenderfer, JN 2018, 'Chimeric antigen receptor T-cell therapies for lymphoma', Nat Rev Clin Oncol, vol. 15, no. 1, Jan, pp. 31-46.Fitzgerald, JC, Weiss, SL, Maude, SL, Barrett, DM, Lacey, SF, Melenhorst, JJ, Shaw, P, Berg, RA, June, CH, Porter, DL, Frey, NV, Grupp, SA & Teachey, DT 2017, 'Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia', Crit Care Med, vol. 45, no. 2, Feb, pp. e124-e131.Hunger, SP, Lu, X, Devidas, M, Camitta, BM, Gaynon, PS, Winick, NJ, Reaman, GH & Carroll, WL 2012, 'Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group', J Clin Oncol, vol. 30, no. 14, May 10, pp. 1663-1669.Institute for Clinical and Economic Review (ICER) 2017, Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value, Draft evidence report, Institute for Clinical and Economic Review.Kirby, T 2014, 'Children's cancer drugs cut into Australian hospital budgets', Lancet Oncol, vol. 15, no. 9, Aug, p. 923.Maude, SL, Frey, N, Shaw, PA, Aplenc, R, Barrett, DM, Bunin, NJ, Chew, A, Gonzalez, VE, Zheng, Z, Lacey, SF, Mahnke, YD, Melenhorst, JJ, Rheingold, SR, Shen, A, Teachey, DT, Levine, BL, June, CH, Porter, DL & Grupp, SA 2014, 'Chimeric antigen receptor T cells for sustained remissions in leukemia', N Engl J Med, vol. 371, no. 16, Oct 16, pp. 1507-1517.Maude, SL, Laetsch, TW, Buechner, J, Rives, S, Boyer, M, Bittencourt, H, Bader, P, Verneris, MR, Stefanski, HE, Myers, GD, Qayed, M, De Moerloose, B, Hiramatsu, H, Schlis, K, Davis, KL, Martin, PL, Nemecek, ER, Yanik, GA, Peters, C, Baruchel, A, Boissel, N, Mechinaud, F, Balduzzi, A, Krueger, J, June, CH, Levine, BL, Wood, P, Taran, T, Leung, M, Mueller, KT, Zhang, Y, Sen, K, Lebwohl, D, Pulsipher, MA & Grupp, SA 2018, 'Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia', N Engl J Med, vol. 378, no. 5, Feb 1, pp. 439-448.Mueller, KT, Maude, SL, Porter, DL, Frey, N, Wood, P, Han, X, Waldron, E, Chakraborty, A, Awasthi, R, Levine, BL, Melenhorst, JJ, Grupp, SA, June, CH & Lacey, SF 2017, 'Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia', Blood, vol. 130, no. 21, Nov 23, pp. 2317-2325.National Cancer Expert Reference Group 2016, Optimal cancer care pathway for people with Hodgkin and diffuse large B-cell lymphomas, Australian Government Cancer Australia and Cancer Council.Novartis 2017, Oncologic drugs advisory committee briefing document. Tisagenlecleucel (CTL019) for the treatment of pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia, FDA Advisory Committee Briefing Document.Porter, DL, Hwang, WT, Frey, NV, Lacey, SF, Shaw, PA, Loren, AW, Bagg, A, Marcucci, KT, Shen, A, Gonzalez, V, Ambrose, D, Grupp, SA, Chew, A, Zheng, Z, Milone, MC, Levine, BL, Melenhorst, JJ & June, CH 2015, 'Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia', Sci Transl Med, vol. 7, no. 303, Sep 2, p. 303ra139.Schuster, SJ, Svoboda, J, Chong, EA, Nasta, SD, Mato, AR, Anak, O, Brogdon, JL, Pruteanu-Malinici, I, Bhoj, V, Landsburg, D, Wasik, M, Levine, BL, Lacey, SF, Melenhorst, JJ, Porter, DL & June, CH 2017, 'Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas', N Engl J Med, vol. 377, no. 26, Dec 28, pp. 2545-2554.'Value in Using CAR T Cells for DLBCL', 2017, Cancer Discov, Dec 15.AppendixThe clinical management algorithms presented in this Appendix (Figures 5 and 6 below) aim to explain the current and proposed approaches to management of any downstream services and outcomes for the proposed populations, once they are identified. This means the starting points for the current management algorithm are the target populations. The blue pathways represent the proposed intervention, with the black pathways representing current management. The dotted lines indicate that patients can drop out at different steps of the treatment process.Figure SEQ Figure \* ARABIC 5 Current and proposed clinical management algorithm for the ALL population (to show downstream effects)Figure SEQ Figure \* ARABIC 6 Current and proposed clinical management algorithm for the DLBCL population (to show downstream effects) ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download